



## **CURRICULUM VITAE**

**Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.**

### **PRESENT TITLE AND AFFILIATION**

#### **Primary Appointment**

Associate Professor, Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX

#### **Dual/Joint/Adjunct Appointment**

Assistant Professor, The University of Texas Medical School at Houston, Houston, TX

### **CITIZENSHIP**

United States  
Canada

### **OFFICE ADDRESS**

The University of Texas MD Anderson Cancer Center  
1400 Pressler Street  
Unit Number: 1471  
Houston, TX 77030-3722  
Room Number: FCT14.6004  
Phone: 713-563-7920  
Fax: 713-792-4098

### **EDUCATION**

#### **Degree-Granting Education**

Brown University, Providence, RI, BS, Honors BSc, 1996, Neuroscience  
University of British Columbia, Vancouver, Canada, MD, 2000, Medicine  
University of California, Irvine, CA, MBA, 2004, Business Administration

#### **Postgraduate Training**

Clinical Internship, General Surgery, Kaiser Permanente Southern California, Los Angeles, CA, JC Collins, M.D., 7/2000-6/2001  
Clinical Residency, Diagnostic Radiology, University of Southern California, Los Angeles, CA, A Wilcox, M.D., 7/2001-6/2005  
Clinical Fellowship, Neuroradiology, University of Southern California, Los Angeles, CA, C Zee, M.D., 7/2004-6/2005  
Clinical Fellowship, Vascular and Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, ME Hicks, M.D., 7/2005-6/2006  
Clinical Quality Assurance, Clinical Safety and Effectiveness Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2011-9/2011

### **CREDENTIALS**

#### **Board Certification**

Royal College of Physicians and Surgeons of Canada, Diagnostic Radiology, 2005  
American Board of Radiology, Diagnostic Imaging, 2005-2020

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

American Board of Radiology, Certificate of Added Qualification in Vascular and Interventional Radiology, 2007-2020

Fellow, Society of Interventional Radiology, 2017

#### **Licensures**

##### **Active**

Medical Council of Canada, Canada, 91059, 2001

Texas Medical Board, M5534, 8/2006-8/2020

##### **Inactive**

California Medical License, A76614, 2001-2011

#### **EXPERIENCE/SERVICE**

##### **Academic Appointments**

Assistant Professor, Department of Diagnostic Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2006-8/2013

Assistant Professor, The University of Texas Medical School at Houston, Houston, TX, 7/2006-present

Associate Professor, Department of Diagnostic Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2013-10/2013

Associate Professor, Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2013-present

##### **Administrative Appointments/Responsibilities**

Chief Resident, Diagnostic Radiology, University of Southern California, Los Angeles, CA, 1/2004-6/2005

IR Fellowship Research Program Coordinator, Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-2012

Director of Clinical Research, Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011-2015

IR Research Seminar Series Chair, Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2011-7/2015

Clinical Medical Director, Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2015-11/2018

##### **Other Appointments/Responsibilities**

Quality Improvement Project: IR Scheduling, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/2011-3/2013

Quality Improvement Project: IPCT Scheduling, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/2011-3/2013

Quality Improvement Project: Development of IR Metrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/2011-present

Quality Improvement Project: IR Inventory Management, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2012-6/2013

Melanoma Moonshots Team Member, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2012-present

Effort Reporting Compliance Work Group, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2012

APOLLO Expansion Working Group, The University of Texas MD Anderson Cancer Center, Houston, TX, 5/2016-present

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

**Endowed Positions**

N/A

**Consultantships**

Galil Medical, Houston, TX, Medical Monitor for MOTION, 12/2015-2018  
MD Anderson Physicians Network, Houston, TX, Consultant, 5/2016-present  
AbbVie Oncology, Chicago, IL, Advisory Board member, 1/2018-1/2019  
Merit Medical, Salt Lake City, UT, Consultant, 1/2018  
Jounce Therapeutics, Boston, MA, Advisory Board Member, 2/2018-2/2020  
Boston Scientific, Minneapolis, MN, Consultant, 2/2019-2/2020  
Endocare, Austin, TX, 4/2019-4/2021

**Military or Other Governmental Service**

N/A

**Institutional Committee Activities**

Clinical Committee for the Development of Hepatocellular Carcinoma Treatment Algorithm, Member, 2008-present  
Clinical Revenues Cycle Committee, Member, 2009-2011  
Strategic Assessment of Clinical Programs Steering Committee, Member, 2011-2012  
Division of Diagnostic Imaging Promotion & Tenure Committee, Member, 2013-present  
Division of Diagnostic Imaging Gender Inclusiveness Promotion & Tenure Committee, Member, 2013-present  
Thoracic/Head and Neck Medical Oncology Biopsy Tissue Steering Committee, Member, 1/2015-present  
Sedation and Procedures Committee, Member, 8/2015-11/2018  
Interventional Radiology Quality Assurance Committee, Chair, 8/2015-11/2018  
Interventional Radiology Clinical Operations Committee, Co-Chair, 8/2015-11/2018  
Interventional Radiology Leadership Committee, Member, 8/2015-11/2018  
DI-Clinical Functional Committee, Member, 8/2015-11/2018  
DI-Quality Functional Committee, Member, 8/2015-11/2018  
Faculty Senate, Member, 2/2016-9/2018  
Medical Quality Planning Committee, Member, 8/2016-present  
Operating Room Subcommittee, Member, 8/2016-present  
Pelvic Sarcoma Center of Excellence, Committee Member, 8/2016-present  
Transfusion & Blood Management Committee, Member, 9/2016-9/2018  
Pleural Work Group Committee, Member, 9/2016-present  
Patient Experience Officer, Member, 11/2017-11/2018

**HONORS AND AWARDS**

Undergraduate Teaching / Research Award, Brown University, 1995  
P. Gerald Marra Scholarship, University of British Columbia, 1997, 1999  
Dr. John J. Mason Memorial Scholarship, University of British Columbia, 1998  
John R. C. Dawlings Memorial Scholarship, University of British Columbia, 1999  
Leadership Academy, Society of Interventional Radiology, 2009

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

Distinguished Faculty Mentoring Award Nominee, The University of Texas MD Anderson Cancer Center, 2013

Fellow, Society of Interventional Radiology (SIR), 2016

Distinguished Faculty mentoring Award Nominee, The University of Texas MD Anderson Cancer Center, 2017

Women Physicians Section Inspirational Physicians Recognition Program Honoree, American Medical Association, 2017

## RESEARCH

### Grants and Contracts

#### Funded

Principal Investigator, 0.12 months, Transportal IRI chemoembolization (TICL), Guerbet LLC, 7/2017-7/2019, \$145,000 (\$72,500/year)

Collaborator, Feasibility Study of Anatomical Modeling for Image Guided Thoracic Surgery, MD Anderson Cancer Center, PI - Guillaume Cazoulat, 1/1/2019-12/31/2020, \$75,000

Program Leader, Strategic Alliance Agreement, 56873, Biocompatibles, PI - Sanjay Gupta, 2/8/2019-2/7/2024, \$5,000,000

#### Pending

Collaborator, Combating intratumoral cancer cell heterogeneity in Ewing sarcoma by co-targeting the EWS-FL11 fusion protein and epigenetic mediators of resistance, MD Anderson Cancer Center, PI - Joseph Ludwig

Site Principal Investigator, Radiomic signature of biologically aggressive hepatocellular carcinoma, NIH/NCI, PI - Nishita Kothary

Collaborator, Targeting PD-1 pathway in resectable hepatocellular carcinoma, NIH/NCI, PI - Ahmed Kaseb

#### Other

N/A

#### Completed

Principal Investigator, A phase IV post approval clinical study of ExAblate treatment of metastatic bone tumors for the palliation of pain, DICRC and Insightec, 5/23/2014-5/22/2016, \$115,296 (\$57,648/year)

Principal Investigator, Visual and functional characterization of nanopore formation after irreversible electroporation in the porcine vertebral body, Society of Interventional Radiology, 6/1/2014-6/1/2015, \$25,000 (\$25,000/year)

Principal Investigator, 1.8 months, Developing an electroporation and nanoparticle-based therapeutic platform for bone metastases: evaluation of local delivery strategies to optimize intratumoral nanoparticle uptake, Radiological Society of North America (RSNA), 7/1/2014-6/30/2015, \$40,000 (\$40,000/year)

Co-Investigator, 0.12 months, Southwest Early Clinical Trials Consortium, 5UM1CA186688-03, NIH/NCI, PI - Meric-Bernstam, 1/3/2015-2/28/2018

Principal Investigator, IRE of spinal metastases in a large animal model, AngioDynamics, 5/27/2015-5/27/2016, \$50,000 (\$25,000/year)

Principal Investigator, Feasibility of using IRE in the treatment of osteomyelitis, AngioDynamics, 6/3/2015-6/2/2017, \$50,000 (\$25,000/year)

Co-Principal Investigator, Low Cost Nanoparticle Platform for Diagnosis and Treatment of Colorectal Liver Metastases, Canadian Radiological Foundation, PI - David Liu, 9/16/2015-9/17/2016, \$5,259 (\$5,259/year)

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

Scientific Advisor, Transportal Irinotecan Chemoembolization using a Lipiodol Nano-emulsion (TICL) for the Treatment of Colorectal Liver Metastases in Rat, Radiological Society of North America (RSNA), PI - Steven Yevich, 7/2017-7/2018, \$40,000 (\$40,000/year)

Principal Investigator, Support of Interventional Radiology (IR) in the Experimental Therapeutics Clinical Trials Network (ETCTN), supplemental grant to Southwest Early Clinical Trials Consortium, 3UM1CA186688-03S4, NIH/NCI, 9/1/2017-2/28/2018, \$148,709 (\$97,708/year)

#### **Not Funded**

Principal Investigator, Automated detection of arterial supply to enhance transarterial tumor therapy, NIH/NCI, 12/2013-11/2015, \$500,000 (\$250,000/year)

Principal Investigator, 1.2 months, Tumor-specific modeling for irreversible electroporation treatment planning of spinal metastases, RFA R-14-IIIRA-1, Cancer Prevention & Research Institute of Texas (CPRIT), 8/31/2014-8/31/2017, \$729,744 (\$243,248/year)

Co-Principal Investigator, Treatment planning for irreversible electroporation of spinal metastases, R21-PAR-13-146, NIH/NCI, 2015-2017, \$274,974 (\$137,487/year)

#### **Protocols**

##### **Funded**

Collaborator, Phase I clinical trial of NPI-0052 in patients with advanced solid tumor malignancies or refractory lymphoma, 2005-0990, PI - Apostolia Maria Tsimberidou, 2006-2014, \$445,600, Nereus Pharmaceutical Inc.

Collaborator, Phase II study of erlotinib, a small molecule targeting epidermal growth factor receptor (EGFR) in the treatment of patients with 'Triple Receptor-Negative' metastatic carcinoma of breast that has progressed on anthracyclines & taxanes, 2006-0613, PI - Ana Maria Gonzalez-Angulo, 2007-2010, \$322,895, OSI Pharmaceuticals, Inc.

Principal Investigator, A phase III randomized trial of cryoablation vs radiation for the palliation of painful bone metastases, NCCTGN06C6, 2008-2009, \$48,000, NCI, NIH, & Endocare

Collaborator, A study to determine correlation of MR thermal imaging to actual size of ablation during laser therapy of soft tissue metastases to bone, 2007-0393, PI - Kamran Ahrar, 2008-2017, \$249,296, Biotex

Co-Principal Investigator, Fluoroscopic guided needle procedures using 2D-3D image overlay (I-Guide), DR08-0739, PI - Michael Wallace, 2009-2012, \$198,613, Siemens

Collaborator, BATTLE-2 Program: A biomarker-integrated study in previously treated patients with advanced non-small cell lung cancer, 2009-0360, PI - Vali Papadimitrakopoulou, 2009-present, \$13,100,000, Merck/Bayer Pharmaceuticals

Collaborator, Novel biomarkers for thoracic tumors, LAB10-0704, PI - Bingliang Fang, 2010, NIH

Principal Investigator, Transcatheter arterial chemoembolization with doxorubicin-loaded LC Beads (DEBDOX) in the treatment of liver-dominant metastases in patients with stage IV metastatic melanoma: A multi-center non-randomized, Feasibility Trial, 2009-0877, 2010-2017, \$64,824, University of Louisville Research Foundation

Collaborator, Assessment of targeted therapies against colorectal cancer (ATTACC Program) Screening protocol, 2009-0091, PI - Scott Kopetz, 2010-present, MDACC Institute for Personalized Therapy

Principal Investigator, Cryoablation for the palliation of painful bone metastases, 2011-0665, 2011-2015, \$37,250, Galil-Medical

Collaborator, Tumor model development and minimally invasive cancer monitoring, LAB10-0982, PI - Scott Kopetz, 2011-present, SPORE

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

Collaborator, A phase II study of MK-2206 in previously treated metastatic colorectal cancer patients enriched for PTEN Loss and PIK3CA mutation, 2012-0431, PI - Scott Kopetz, 2012-2018, NCI, Cancer Prevention Research Institute of Texas

Collaborator, A phase I, open-label, dose escalation study of oral LGK974 in patients with melanoma and lobular breast cancer, 2011-0686, PI - Filip Janku, 2012-present, Novartis

Collaborator, A phase I/II, open label, safety, PK and preliminary efficacy study of oral CO-1686 in patients with previously treated mutant EGFR NSCLC, 2012-0009, PI - Vali Papadimitrakopoulou, 2013-2017, Clovis Oncology, Inc.

Collaborator, A phase II study of Neratinib and Neratinib plus Temeolimus in patients with non-small cell lung cancer carrying known HER2 activating mutations, 2013-0572, PI - Bonnie Glisson, 2013-2017, Puma Biotechnology, Inc.

Collaborator, An open-label, multicenter, corollary study of pre-operative therapy with single agent GSK2118436 in subjects with BRAF mutation-positive metastatic melanoma to the brain, 2012-0208, PI - Michael Davies, 2013-2017, GlaxoSmithKline

Collaborator, A phase 1b/2 study of safety and efficacy of MLN0128 (Dual TORC 1/2 Inhibitor) in combination with exemestane or fulvestrant therapy in postmenopausal women with ER+/HER2-advanced or metastatic breast cancer that has progressed on treatment with everolimus in combination with exemestane or fulvestrant, 2013-0776, PI - Bora Lim, 2013-present, F. Hoffman-La Roche Ltd.

Collaborator, A phase I/II clinical trial evaluating Dcvax-direct, autologous activated dendritic cells for intratumoral injection, in patients with solid tumors, 2013-0160, PI - Vivek Subbiah, 2013-present, Northwest Biotherapeutics

Collaborator, A phase II study of sorafenib and yttrium-90 glass microspheres for advanced hepatocellular carcinoma, BCLC stage C, 2012-0870, PI - Ahmed Kaseb, 2013-present, Bayer

Collaborator, Investigating Immunobiology in Cancer Patients, PA13-0291, PI - P Sharma, 2013-present, Immunotherapy Platform

Collaborator, Phase 1 study to determine the effects of mesenchymal stem cells secreting interferon beta in patients with advanced ovarian cancer, 2013-0032, PI - Amanda Olson, 2013-present, Ovarian Cancer SPORE Grant

Collaborator, A phase III, open label, randomized study of AZD9291 versus platinum- based doublet chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy and whose tumors harbor a T790M mutation within the epidermal growth factor receptor gene (AURA3), 2014-0523, PI - Kathryn Gold, 2014-2015, AstraZeneca

Principal Investigator, Multi-center study of metastatic lung tumors targeted by interventional cryoablation evaluation (SOLSTICE), 2014-0093, 2014-2015, Galil-Medical

Principal Investigator, A phase IV post approval clinical study of exAblate treatment of metastatic bone tumors for the palliation of pain, 2013-0736, 2014-2016, InSightec

Collaborator, A phase 1 study to evaluate the safety, pharmacokinetics, and pharmacodynamics of JNJ-42756493, a pan-Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in subjects with advanced or refractory solid tumors or lymphoma, 2013-0551, PI - Vali Papadimitrakopoulou, 2014-2017, Janssen Research & Development

Collaborator, A phase I dose escalation study of OMP-52M51 in subjects with solid tumors, 2014-0411, PI - Renata Ferrarotto, 2014-2017, OncoMed Pharmaceuticals, Inc

Collaborator, TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC), 2014-0803, PI - Vali Papadimitrakopoulou, 2014-2017, Clovis Oncology, Inc.

Collaborator, A dose-escalation, phase I/II, open-label, three-part study of the MEK inhibitor, trametinib, combined with the CDK4/6 inhibitor, palbociclib, to investigate the safety,

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

pharmacokinetics, pharmacodynamics, and anti-cancer activity in subjects with solid tumors, 2013-0793, PI - Michael Davies, 2014-2018, GlaxoSmithKline

Collaborator, A phase 2 clinical trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite high (MSI-H) colon cancer (CA209142, 2013-1015, PI - Michael Overman, 2014-2018, Bristol-Myers Squibb

Collaborator, A phase I, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ascending doses of AZD9291 in patients with advanced non-small cell lung cancer who have progressed following prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor agent (AURA), 2013-0537, PI - Vali Papadimitrakopoulou, 2014-2018, AstraZeneca Pharmaceuticals LP

Collaborator, An open-label, multicenter, dose-escalation, phase 1b/2 study of the safety, efficacy, pharmacodynamics, and pharmacokinetics of RTA 408 in combination with Ipilimumab in the treatment of patients with unresectable or metastatic melanoma, 2014-0613, PI - Pradyuman Patel, 2014-2018, Reata Pharmaceuticals

Collaborator, BRF117277: A phase II, open-label, multicentre study of Dabrafenib plus Trametinib in subjects with BRAF mutation- positive melanoma that has metastasized to the brain, 2013-1020, PI - Michael Davies, 2014-2018, Amgen, AstraZeneca, Genentech, Medimmune, NCI, Pfizer

Collaborator, Phase 2, open-label study of Rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation (CO-338-023), 2014-0151, PI - Rachna Shroff, 2014-2018, Clovis Oncology

Co-Principal Investigator, A multimodality image-guided system for peripheral lung cancer diagnosis and therapy, 2011-0368, PI - Marshall Hicks, 2014-present, The Methodist Hospital

Collaborator, A phase 1/2 dose escalation and cohort expansion study of the safety and tolerability of Urelumab administered in combination with Nivolumab in advanced/metastatic solid tumors and B cell non-hodgkins lymphoma, 2014-0651, PI - Vali Papadimitrakopoulou, 2014-present, Bristol-Myers Squibb

Collaborator, A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736 in combination with Tremelimumab in subjects with advanced non-small cell lung cancer, 2014-0109, PI - Vali Papadimitrakopoulou, 2014-present, Medimmune

Collaborator, A phase 1b trial of LY2606368 in combination with Cisplatin or Cetuximab in advanced and/or metastatic tumors, 2014-0193, PI - David Hong, 2014-present, Eli Lilly

Collaborator, A phase I/II multicenter, open-label safety, pharmacokinetic and preliminary efficacy study of wild-type sparing EGFR inhibitor, AC0010MA, in adult patients with previously treated EGFRmut and T790M mutation non-small cell lung cancer (NSCLC), 2014-0863, PI - Vali Papadimitrakopoulou, 2014-present, ACEA Bioscience, Inc.

Collaborator, A phase I/II study of MK-3475 (SCH900475) in combination with chemotherapy or immunotherapy in patients with locally advanced or metastatic non-small cell lung carcinoma, 2013-0984, PI - Vali Papadimitrakopoulou, 2014-present, Merck & Co.

Collaborator, A phase II clinical trial of single agent Pembrolizumab (MK-3475) in subjects with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and cetuximab, 2014-0819, PI - George Blumenschein, Jr., 2014-present, Merck Sharp and Dohme, Merck & Co.

Collaborator, A phase II open-label, two-arm study of the MEK inhibitor, trametinib, to investigate the safety and anti-cancer activity in subjects with melanoma with BRAF non-V600 mutations, 2014-0766, PI - Michael Davies, 2014-present, NCCN, Douglas Johnson, MD

Collaborator, A phase II/III randomized trial of two doses of MK-3475 (SCH900475) versus Docetaxel in previously treated subjects with non-small cell lung cancer, 2013-0691, PI - Vali Papadimitrakopoulou, 2014-present, Merck & Co.

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

Collaborator, A Pilot Study of Tremelimumab With or Without Tissue Cryoablation in Patients with Metastatic Renal Cell Carcinoma, 2013-0539, PI - Padmanee Sharma, 2014-present, MDACC, Medimmune

Collaborator, A randomized phase 2 study of AP26113 in patients with ALK-positive, non-small cell lung cancer (NSCLC) previously treated with Crizotinib, 2014-0144, PI - Kathryn Ann Gold, 2014-present, Ariad Pharmaceuticals, Inc.

Collaborator, First-in-human, dose-escalating safety study of tissue factor specific antibody drug conjugate (HuMax-TF-ADC) in patients with locally advanced and/or metastatic solid tumors known to express tissue factor, 2013-0699, PI - David Hong, 2014-present, Genmab

Collaborator, Neoadjuvant and adjuvant Dabrafenib and Trametinib compared to surgery in patients with clinical stage III or Oligometastatic stage IV melanoma (Combi-Neo), 2014-0409, PI - Jennifer Wargo, 2014-present, GlaxoSmithKline

Collaborator, Phase 1 study of Mogamulizumab (KW-0761) in combination with MEDI4736 and Mogamulizumab in combination with Tremelimumab in subjects with advanced, 2014-0763, PI - David Hong, 2014-present, Kyowa Hakko Kirin Pharma, Inc

Collaborator, Phase II trial of Alisertib (MLN8237) in salvage malignant mesothelioma, 2014-0497, PI - Anne Tsao, 2014-present, MDACC, Millennium

Collaborator, Phase II/III biomarker-driven master protocol for second line therapy of squamous cell lung cancer, SWOGS1400, PI - Vali Papadimitrakopoulou, 2014-present, Amgen, AstraZeneca, Genentech, Medimmune, NCI, Pfizer

Collaborator, Open-label, multicenter phase 1 study of Mogamulizumab (KW-0761) in combination with Docetaxel as second-line treatment in subjects with non-small cell lung cancer (NSCLC), 2015-0609, PI - Vali Papadimitrakopoulou, 2015-2017, Kyowa Hakko Kirin Pharma, Inc

Collaborator, A phase 2 proof-of-concept study of ACP-196 alone and in combination with pembrolizumab in subjects with advanced or metastatic pancreatic cancer (ACE-ST-003), 2014-1080, PI - Michael Overman, 2015-2018, Acerta Pharma, Inc.

Collaborator, A multi-center phase 2 open-label study to evaluate safety and efficacy in subjects with melanoma metastatic to the brain treated with Nivolumab in Combination with Ipilimumab followed by Nivolumab monotherapy, 2015-0696, PI - Hussein Tawbi, 2015-present, Bristol-Myers Squibb

Collaborator, A phase 2, multicenter, international, single arm study to assess the safety and efficacy of single agent CC-486 (Oral Azacitidine) in previously treated subjects with locally advanced or metastatic nasopharyngeal carcinoma, 2015-0066, PI - Renata Ferrarotto, 2015-present, Celgene

Collaborator, A phase I, open-label, dose-finding study of GSK2636771 administered in combination with Enzalutamide (Xtandi) in male subjects with metastatic castration-resistant prostate cancer (mCRPC), 2015-0379, PI - Ana Aparicio, 2015-present, GlaxoSmithKline

Collaborator, A phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies, 2015-0263, PI - David Hong, 2015-present, Novartis

Collaborator, A Phase I/II, Open-Label, Multicenter, Dose-Escalation Study of NKTR-214 in Subjects with Advanced or Recurrent Solid Tumor Malignancies, 2015-0573, PI - Adi Diab, 2015-present, Nektar Therapeutics

Collaborator, A phase II basket study of the oral TRK inhibitor LOXO-101 in subjects with NTRK fusion-positive tumors, 2015-0728, PI - David S. Hong, 2015-present, Loxo Oncology

Collaborator, A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following



Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

treatment with a platinum agent (CA209-275), 2014-1031, PI - Padmanee Sharma, 2015-present, Bristol Myers Squibb

Collaborator, A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult patients with cMet positive non-small cell lung cancer, 2015-0194, PI - Vali Papadimitrakopoulou, 2015-present, Bristol-Myers Squibb, Novartis

Collaborator, A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) in Combination with Carboplatin + NAB-Paclitaxel for Chemotherapy -Naive Patients with Stage IV Non-Squamous Non-Small Cell Lung C, 2015-0559, PI - Vali Papadimitrakopoulou, 2015-present, F. Hoffmann-La Roche Ltd

Collaborator, A phase III, multicenter, randomized, open-label study evaluating the efficacy and safety of MPDL3280A (Anti-PD-L1 Antibody) in combination with Carboplatin + NAB-Paclitaxel for chemotherapy -naive patients with stage IV non-squamous non-small cell lung cancer, 2015-0059, PI - Vali Papadimitrakopoulou, 2015-present, F. Hoffmann-La Roche Ltd

Collaborator, An open-label non-randomized, multicenter phase I study to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose of oral MKNK1 inhibitor BAY 1143269 given alone or in combination with intravenous Docetaxel, 2015-0627, PI - Funda Meric-Bernstam, 2015-present, Bayer

Collaborator, Dose-escalating safety trial of tissue factor specific antibody drug conjugate (HuMax-TF-ADC) in patients with locally advanced and/or metastatic solid tumors known to express tissue factor, 2015-0597, PI - David S. Hong, 2015-present, Genmab

Collaborator, Neoadjuvant and Adjuvant Checkpoint Blockade in Patients with Clinical Stage III or Oligometastatic Stage IV Melanoma, 2015-0041, PI - Rodabe Amaria, 2015-present, Bristol-Myers Squibb, MDACC

Collaborator, Phase 1b/2a safety and pharmacokinetic study of G1T28 in patients with previously treated extensive-stage small cell lung cancer (SCLC) receiving Topotecan chemotherapy, 2015-0545, PI - Renata Ferrarotto, 2015-present, G1 Therapeutics

Collaborator, Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer, 2014-1003, PI - James Welsh, 2015-present, Merck & Co.

Collaborator, Phase I/II trial of MK-3475 and hypofractionated stereotactic radiation therapy in patients with NSCLC, 2014-1020, PI - James Welsh, 2015-present, Merck & Co.

Collaborator, Phase II study of MK-3475 in conjunction with Lymphodepletion, TIL, and high or low dose IL-2 in patients with metastatic melanoma, 2014-0922, PI - Rodabe Amaria, 2015-present, MDACC, Merck & Co.

Collaborator, Pilot study of feasibility and safety of personalized autologous CD8+ T cell therapy plus anti-PD1Antibody in advanced solid malignancies, 2015-0152, PI - Cassian Yee, 2015-present, MDACC

Collaborator, Pilot study of the feasibility and safety of a personalized peptide vaccine in patients with advanced pancreatic ductal adenocarcinoma or colorectal adenocarcinoma, 2014-1029, PI - Michael Overman, 2015-present, MDACC

Collaborator, A New Guide for our Guided-Bronchoscopy: The use of Cone-Beam CT to Enhance Navigation and Diagnostic Yield of RP-EBUS and Hybrid Bronchoscope for Peripheral Lung Nodules Suspicious for Malignancy: A Pilot Study, 2016-0466, PI - Roberto Casal, 2016-2018, Siemens Medical

Collaborator, A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Subjects with Select Adv, 2016-0135, PI - Michael Overman, 2016-present, Medimmune

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

Collaborator, A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients with Advanced Tumors and Lymphomas, 2016-0834, PI - Funda Meric-Bernstam, 2016-present, Curis

Collaborator, A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects with Advanced Solid Tumors, 2016-0345, PI - Funda Meric-Bernstam, 2016-present, Effective Pharmaceuticals

Collaborator, A phase 1/2 study of the safety, pharmacokinetics, and pharmacodynamics of the glutaminase inhibitor CB-839 in combination with Nivolumab in patients with clear cell renal cell carcinoma and other solid tumors, 2016-0270, PI - Funda Meric Bernstam, 2016-present, Calithera Biosciences, Inc.

Collaborator, A phase I/II study of Pembrolizumab (MK-3475) in subjects with advanced hepatocellular carcinoma who progressed on or were intolerant to first-line systemic therapy, 2016-0261, PI - Ahmed Kaseb, 2016-present, STRATEGIC ALLIANCE: Merck

Collaborator, A phase I/II study of Pembrolizumab (MK-3475) in subjects with advanced hepatocellular carcinoma who progressed on or were intolerant to first-line systemic therapy, 2016-0251, PI - Ahmed Kaseb, 2016-present, Merck

Collaborator, A Phase II Study of Poziotinib in EGFR in Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC), 2016-0783, PI - John Victor Heymach, 2016-present, Spectrum Pharmaceuticals

Collaborator, A phase II study of the anti-PD-1 antibody Nivolumab in combination with Dabrafenib and/or Trametinib in patients with BRAF or NRAS-mutated metastatic melanoma, 2015-0605, PI - Hussein Tawbi, 2016-present, MDACC, BMS

Collaborator, A phase IIb pilot study to assess the efficacy, safety and pharmacodynamics effects of Pembrolizumab and BL-8040 in patients with metastatic pancreatic cancer, 2016-0410, PI - David Fogelman, 2016-present, MDACC, BiolineRX, Ltd., Merck Sharp & Dohme Corp.

Collaborator, An open-label study of Rovalpituzumab Tesirine in subjects with delta-like protein 3-expressing advanced solid tumors, 2016-0346, PI - David Hong, 2016-present, Stem CentRx, Inc.

Collaborator, Phase 1 trial of ZW25 alone and in combination with chemotherapy or immunotherapy in patients with HER2-expressing cancers, 2016-0532, PI - Funda Meric-Bernstam, 2016-present, Zymeworks, Inc.

Collaborator, Phase 1/2 multicenter trial of ICOS agonist monoclonal antibody (mAb) JTX-2011 alone or in combination with Nivolumab in adult subjects with advanced refractory solid tumor malignancies, 2016-0386, 2016-present, Jounce Therapeutics

Collaborator, Phase I/II dose escalation and cohort expansion of safety and tolerability study of intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic Pembrolizumab in patients with metastatic melanoma, 2015-0654, PI - Adi Diab, 2016-present

Collaborator, Phase II clinical trial evaluating intravenous AZD9150 (antisense STAT3) with MEDI4736 (anti-PD-L1) in patients with advanced pancreatic, non-small cell lung cancer, and mismatch repair deficient colorectal cancer, 2016-0108, PI - David Hong, 2016-present, MDACC, AstraZeneca

Collaborator, Pilot study assessing the safety and tolerability of the Neoadjuvant Use of Tremelimumab (anti-CTLA-4) plus Durvalumab (MEDI4736) (anti-PD-L1) in the treatment of resectable colorectal cancer liver metastases, 2015-0828, PI - Michael Overman, 2016-present, MDACC, Strategic Alliance: Medimmune

Collaborator, A phase 3, randomized, open-label study of Nivolumab combined with Cabozantinib versus Sunitinib in participants with previously untreated advanced or metastatic

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

renal cell carcinoma (CheckMate 9ER: CHECKpoint pathway and nivolumab clinical trial evaluation, 2017-0402, PI - Amishi Yogesh Shah, 2017-2018, Bristol-Myers Squibb

Collaborator, An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer, 2017-0331, PI - Vali Papadimitrakopoulou, 2017-2018, Incyte

Collaborator, A randomized, double-blind, placebo-controlled phase 2 study comparing CB-839 in combination with Everolimus (CBE) vs. placebo with Everolimus (PboE) in patients with advanced or metastatic renal cell carcinoma (RCC), 2017-0333, PI - Nizar Tannir, 2017-2019, Calithera Biosciences, Inc.

Collaborator, A multiarm, open-label, multicenter, phase 1b/2 study to evaluate novel combination therapies in subjects with previously treated advanced EGFRm NSCLC, 2017-0891, PI - Vali Papadimitrakopoulou, 2017-present, Medimmune

Collaborator, A phase 1 dose escalation study evaluating the safety and tolerability of PF-06804103 in patients with human epidermal growth factor receptor 2 (HER2) positive solid tumors, 2017-0539, PI - Funda Meric-Bernstam, 2017-present, Pfizer

Collaborator, A phase 1B, randomized, open-label study of PEGylated recombinant human Hyaluronidase (PEGPH20) in combination with Cisplatin plus Gemcitabine and PEGPH20 in combination with Atezolizumab and Cisplatin plus Gemcitabine compared with Cisplatin plus Gemcitabine, 2017-0553, PI - Rachna Shroff, 2017-present, Halozyme

Collaborator, A phase 2 study of Poziotinib in patients with non-small cell lung cancer, locally advanced or metastatic, with EGFR or HER2 Exon 20 insertion mutation (POZITIVE20-1), 2017-0857, PI - John Victor Heymach, 2017-present, Spectrum Pharmaceuticals

Collaborator, A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, Dabrafenib and Trametinib versus placebo, Dabrafenib and Trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma, 2017-0134, PI - Hussein Tawbi, 2017-present, Novartis

Collaborator, Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors with Ras Pathway Alterations, and Ovarian Tumors with PARP Resistance, 2016-1129, PI - Shannon Westin, 2017-present, AstraZeneca, MDACC, Institutional Moon Shot Fund

Collaborator, IM-BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer, 2017-0226, PI - Vali Papadimitrakopoulou, 2017-present, MDACC, NCI, Novartis, Merck & Co

Collaborator, Phase I/II Study of the selective PI3K-beta inhibitor GSK2636771 in Combination with Pembrolizumab in patients with Metastatic Melanoma and PTEN Loss, 2016-0774, PI - Hussein Tawbi, 2017-present, GlaxoSmithKline, MDACC, NCI, Merck Sharp & Dohme Corp, Moon Shot Program

Collaborator, Phase I/II Trial of MGCD516 Combined with Nivolumab in Patients with Advanced Clear Cell Renal Cell Cancer That Progressed On Prior VEGF-Targeted Therapy, 2016-0332, PI - Nizar Tannir, 2017-present, MDACC, Mirati Therapeutics, Inc.

Collaborator, Phase II clinical trial evaluating intravenous AZD9150 (antisense STAT3) with MEDI4736 (anti-PD-L1) in patients with advanced pancreatic, non-small cell lung cancer, and mismatch repair deficient colorectal cancer, 2016-0108, PI - David Hong, 2017-present, AstraZeneca, MDACC

Collaborator, Randomized phase III trial of local consolidation therapy (LCT) after Nivolumab and Ipilimumab for immunotherapy-naive patients with metastatic non-small cell lung cancer (LONESTAR), 2017-0311, PI - John Heymach, 2017-present, MDACC, BMS

Collaborator, An open-label phase 1b/2 study of Binimetinib administered in combination with Nivolumab or Nivolumab plus Ipilimumab in patients with previously treated microsatellite-

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

stable (MSS) metastatic colorectal cancer with RAS mutation (ARRAY 162-202), 2017-0995, PI - Scott Kopetz, 2018, Array BioPharma

Collaborator, A multicenter, two-part, phase 1b clinical study of CMP-001 in combination with Atezolizumab with and without radiation therapy in subjects with advanced non-small cell lung cancer (NSCLC), 2017-1015, PI - Vali Papadimitrakopoulou, 2018-present, Checkmate Pharmaceuticals, Inc.

Collaborator, A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma, 2018-0430, PI - Michael Overman, 2018-present, Medimmune

Collaborator, A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma, 2018-0430, PI - Michael Overman, 2018-present, Medimmune

Collaborator, A Phase I Radiation and CHECKpoint bLockade trial in patients with metastatic hormone receptor positive, HER2 negative breast cancer, 2017-0499, PI - Jennifer Litton, 2018-present, MDACC

Collaborator, A Phase Ib trial of M7824 and Eribulin in Patients with Metastatic Triple Negative Breast Cancer (TNBC), 2017-0500, PI - Jennifer Litton, 2018-present, MDACC, Strategic Alliance: EMD Serono and MDA IND

Collaborator, A Phase Ib trial of M7824 and Eribulin in Patients with Metastatic Triple Negative Breast Cancer (TNBC), 2017-0500, PI - Jennifer Litton, 2018-present, MDACC, STRATEGIC ALLIANCE: EMD Serono and MDA IND

Collaborator, A Pilot Single Arm Open Label Trial Evaluating M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients with Stage II-III HER2/neu Positive (HER2+) Breast Cancer (BC), 2017-0502, PI - Jennifer Litton, 2018-present, MDACC, EMD Serono

Collaborator, A Pilot Single Arm Open Label Trial Evaluating M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients with Stage II-III HER2/neu Positive (HER2+) Breast Cancer (BC), 2018-0220, PI - Nizar Tannir, 2018-present, Calithera Biosciences, Inc.

Collaborator, A Pilot Single Arm Open Label Trial Evaluating M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients with Stage II-III HER2/neu Positive (HER2+) Breast Cancer (BC), 2017-0502, PI - Murthy, Rashmi Krishna, 2018-present, MDACC, EMD Serono

Collaborator, A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC), 2018-0220, PI - Nizar Tannir, 2018-present, Calithera Biosciences, Inc.

Collaborator, An Open-Label, Multi Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients with Non-Small Cell Lung Cancer, who Progressed on an anti-PD-1/PD-L1 Containing Therapy (HUDSON), 2018-0327, PI - John Heymach, 2018-present, AstraZeneca

Co-Principal Investigator, An Open-Label, Multi Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients with Non-Small Cell Lung Cancer, who Progressed on an anti-PD-1/PD-L1 Containing Therapy (HUDSON), 2018-0327, PI - John Heymach, 2018-present, AstraZeneca

Collaborator, Bronchoscopic Laser Ablation of Solid Peripheral Lung Tumors followed by Surgical Resection (BLAST-SR Trial), 2018-0474, PI - Roberto Casal, 2018-present, Siemens Medical, Convergent

Collaborator, EXTERNAL Beam Radiation to Eliminate Nominal Metastatic Disease (EXTEND): A Randomized Phase II Basket Trial Assessing the Efficacy of Upfront Local Consolidative Therapy (LCT) for Oligometastatic Disease, 2018-0349, PI - Chad Tang, 2018-present, CPRIT

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

Collaborator, EXTERNAL BEAM RADIATION TO ELIMINATE NOMINAL METASTATIC DISEASE (EXTEND): A Randomized Phase II Basket Trial Assessing the Efficacy of Upfront Local Consolidative Therapy (LCT) for Oligometastatic Disease, 2018-0349, PI - Tad Chang, 2018-present, CPRIT

Collaborator, RACHEL1: A Phase I Radiation and CHECKPOINT BLOCKADE TRIAL IN PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER, 2017-0499, PI - Jennifer Litton, 2018-present, MDACC

Collaborator, A phase Ib/II trial of M7824 in solid tumors with microsatellite instability or with Consensus Molecular Subtype 4 metastatic colorectal cancer, 2017-0339, PI - Van Morris, 2018, MDACC, Merck & Co., EMD Serono

Collaborator, Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients with Sarcomas, 2019-0171, PI - Joseph Ludwig, 2019-present, Cancer Center Support Grant

Collaborator, Phase I/II Trial of Encorafenib, Cetuximab, and Nivolumab in Microsatellite Stable BRAFV600E Metastatic Colorectal Cancer (BMS-MDACC CA209-8P6/ARRAY IST-818-101X), 2018-0993, PI - Van Morris, 2019, Bristol-Myers Squibb, Array

#### **Unfunded**

Collaborator, Pancreas tissue bank, LAB00-396, PI - Rosa Hwang, 2000-present

Collaborator, Prospective tissue bank for patients with or suspected to have genitourinary malignancies, LAB02-152, PI - Christopher Logothetis, 2002-present

Co-Principal Investigator, Liver abscess after inadvertent transhepatic transgression of a percutaneous fluoroscopic guided gastrostomy, RCR07-0016, PI - Ravi Murthy, 2005-2007

Principal Investigator, Clinical utility of bronchial artery embolization - a retrospective analysis, RCR06-0731, 2005-2008

Principal Investigator, Percutaneous image-guided spleen biopsies, RCR04-0777, 2005-2008

Principal Investigator, Registry to evaluate the safety of air travel following lung biopsy, PCR06-1042, 2005-2011

Collaborator, Hepatic artery embolization and chemoembolization for the treatment of liver metastases from melanomas, RCR06-0912, PI - Sanjay Gupta, 2007-2009

Collaborator, Registry for magnetic resonance imaging guided biopsies, DR07-0726, PI - Judy Ahrar, 2007-2014

Principal Investigator, C-arm cone beam CT needle pain overlay for fluoroscopic guided vertebroplasty retrospective chart review, DR08-0298, 2008-2009

Collaborator, Comparison of the RECIST and EASL criteria for radiologic response analysis after HAE/HACE for primary and secondary malignant liver tumors, DR07-0603, PI - Sanjay Gupta, 2008-2009

Principal Investigator, Image guided drainage of pericardial effusions in oncology patients, DR08-0111, 2008-2009

Principal Investigator, Safety of early tube feedings following placement of percutaneous fluoroscopically placed gastrostomy tubes, DR08-0562, 2008-2014

Principal Investigator, Intraperitoneal catheter placement for the management of malignant ascites--retrospective data review, DR08-0285, 2008-present

Principal Investigator, Fluoroscopic guided gastrostomy in patients with ascites – retrospective chart review, DR09-0145, 2009-2014

Collaborator, Creation of adenocarcinoma of the small bowel cell line, LAB09-0006, PI - Michael Overman, 2009-present

Collaborator, Evaluation and refinement of interventional and intra-operative MRI software, DR08-0762, PI - Kamran Ahrar, 2009-present

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

Collaborator, A humanitarian device exemption treatment protocol of TheraSphere for treatment of unresectable hepatocellular carcinoma, 2008-0770, PI - Armeen Mahvash, 2010-present

Collaborator, Collection of residual tissue and blood for analyses from patients with biliary tract cancers, PA11-0826, PI - Rachna Shroff, 2010-present

Collaborator, Evaluation of immunologic responses after renal ablative therapy, Lab09-0383, PI - Surena Matin, 2010-present

Principal Investigator, Transarterial chemoembolization in the management of patients with primary liver cancer and secondary metastases to the liver, DR10-0320, 2010-present

Principal Investigator, Dyna CT and percutaneous fluoroscopic gastrostomy tube placement: does the use of Dyna CT increase the likelihood of success and decrease the likelihood of complications with gastrostomy tube placement, DR10-0871, 2011

Collaborator, Biliary drainage in patients with advanced hilar biliary obstruction, DR11-0032, PI - Michael Wallace, 2011-2014

Collaborator, BATTLE-FL: A biomarker-integrated study in patients with advanced non-small cell lung cancer treated in the front-Line (FL) setting, 2010-0097, PI - George Simon, 2011-2017

Collaborator, Biliary drainage in patients with advanced biliary obstruction, DR11-0032, PI - Michael Wallace, 2011-present

Co-Principal Investigator, Safety and efficacy of combined treatment with radiofrequency ablation and hepatic arterial embolization for the treatment of primary and secondary malignant hepatic neoplasms: a retrospective evaluation, PA11-0569, PI - Sanjay Gupta, 2011-present

Principal Investigator, Reversing post-cryoablation neurapraxia with steroid therapy: A report of four cases and review of the literature, PA12-0440, 2012-2014

Collaborator, A prospective study using implanted fiducial markers to assess treatment accuracy and esophageal toxicity in spinal SBRT, 2012-0190, PI - Amoi Ghia, 2012-present

Principal Investigator, Evaluation of risks, benefits and complications from research biopsies, PA12-0170, 2012-present

Collaborator, Randomized phase III study of sorafenib versus stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma, RTOG1112, PI - Sunil Krishnan, 2012-present

Collaborator, A phase 1/2, open-label study of Nivolumab monotherapy or Nivolumab combined with Ipilimumab in subjects with advanced or metastatic solid tumors (CA209032), 2013-0639, PI - Padmanee Sharma, 2013-present

Collaborator, A phase 2 clinical trial of Nivolumab and Nivolumab plus Ipilimumab in recurrent and metastatic microsatellite high (MSI-H) colon cancer, 2013-1015, 2013-present

Collaborator, Feasibility of using ex-vivo optical coherence microscopy (OCM) for immediate assessment of specimen cellularity during image guided percutaneous core needle biopsy, PA11-1089, PI - Sharjeel Sabir, 2013-present

Collaborator, Longitudinal biopsy tissue acquisition protocol, 2012-0846, PI - Jennifer Wargo, 2013-present

Collaborator, Safety and efficacy of palliative venting gastrostomy, PA12-0914, PI - Steven Huang, 2013-present

Collaborator, Safety of transarterial hepatic chemoembolization using a new drug-eluting bead platform ranging from 70-150um: a retrospective evaluation, PA14-0503, PI - Bruno Odisio, 2014-2015

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

Collaborator, A phase I/II study of Ibrutinib in previously treated EGFR mutant non-small cell lung cancer, 2014-0602, PI - John Heymach, 2014-present, MDACC, Pharmacocyclics

Collaborator, A prospective re-biopsy and tissue collection protocol for patients with thoracic malignancies progressing on therapy, PA14-0531, PI - Bonnie Glisson, 2014-present

Collaborator, Interventional radiology image guided biopsies outcomes project within MDACC, PA13-0322, PI - Sharjeel Sabir, 2014-present

Collaborator, A phase 1a/b dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of OMP-131R10 in advanced solid tumors and in combination with FOLFIRI for patients with previously treated metastatic colorectal cancer (131R10-001), 2015-0721, PI - Van Morris, 2015-2019, OncoMed Pharmaceuticals, Inc

Collaborator, Molecular analysis for therapy choice (NCI-MATCH), ECOGEAY131, PI - Funda Meric-Bernstam, 2015-present

Co-Principal Investigator, Patient skin doses during CT-guided interventions, PA15-0034, PI - Aaron K. Jones, 2015-present

Principal Investigator, SPECT Imaging Acquired in the Angiography Suite: Utility for Y90 Procedures, 2015-0797, 2015-present

Collaborator, Evaluation of Percutaneous Adrenal Ablation, PA16-1028, PI - Sharjeel Sabir, 2016-present

Principal Investigator, Percutaneous Image Guided Ablation of Oligometastatic Disease to Bone for Local Oncologic Control in Renal Cell Carcinoma, PA15-0996, 2016-present

Collaborator, Retrospective review of clinical characteristics, imaging findings, and outcome of patients with pulmonary embolism, PA15-1002, PI - Carol Wu, 2016-present

Collaborator, To study efficacy of treatment of aneurysmal and unicameral bones cysts with percutaneous intralésional Doxycycline and steroid injections, PA16-0036, PI - Rajendra Kuman, 2016-present

Collaborator, Retrospective evaluation of the potential clinical utility for dual energy and metal artifact correction Computed Tomography (CT) algorithms on the visualization of therapeutic ice ball in CT-guided cryoablation of musculoskeletal malignancies, PA17-0825, PI - Steven Yevich, 2017-present

Co-Principal Investigator, Retrospective review of intratumoral drug delivery interventions, PA18-0650, PI - Rahul Sheth, 2018-present

#### **Patents and Technology Licenses**

##### **Patents**

MD Anderson Cancer Center, Tissue Sampling System, United States, Serial No. 15/138,536, 4/26/2016, Filed

##### **Technology Licenses**

N/A

#### **Grant Reviewer/Service on Study Sections**

Human Cortical Physiology Section, NIH, Summer Intern, 1997-1998

Arizona Biomedical Research Commission Proposal Panel, State, Member, 2009-2012

#### **PUBLICATIONS**

##### **Peer-Reviewed Original Research Articles**

1. Chen R, **Tam A**, Bütetisch C, Corwell B, Ziemann U, Rothwell JC, Cohen LG. Intracortical inhibition and facilitation in different representations of the human motor cortex. *J Neurophysiol* 80(6):2870-2881, 1998. PMID: 9862891.
2. Mahabir RC, Son-Hing J, Tam AL, Vastardis AD. Ancient Indian civilization: ahead by a nose. *J Invest Surg* 14(1):3-5, Jan-Feb, 1/2001. PMID: 11297058.

3. Ziemann U, **Tam A**, Bütefisch C, Cohen LG. Dual modulating effects of amphetamine on neuronal excitability and stimulation-induced plasticity in human motor cortex. *Clin Neurophysiol* 113(8):1308-15, 8/2002. PMID: 12140012.
4. **Tam AL**, Camberos A, Applebaum H. Surgical decision making in necrotizing enterocolitis and focal intestinal perforation: predictive value of radiologic findings. *J Pediatr Surg* 37(12):1688-1691, 2002. PMID: 12483631.
5. Marx MV, **Tam A**, Teitelbaum G. SIR 2005 annual meeting film panel case: traumatic pericallosal pseudoaneurysm. *J Vasc Interv Radiol* 16(5):631-644, 2005. PMID: 15872316.
6. Marx MV, Haskal ZJ, Kaufman JA, LaBerge J, Nemecek AA, Sohn J, **Tam A**, Van Allan RJ. SIR 2005 Annual Meeting Film Panel Case: traumatic pericallosal pseudoaneurysm. *Vasc Interv Radiol* 16(21):173-194, 2005.
7. **Tam A**, Krishnamurthy S, Pillsbury EP, Ensor JE, Gupta S, Murthy R, Ahrar K, Wallace MJ, Hicks ME, Madoff DC. Percutaneous image-guided splenic biopsy in the oncology patient: an audit of 156 consecutive cases. *J Vasc Interv Radiol* 19(1):80-87, 1/2008. PMID: 18192471.
8. **Tam A**, Wagner-Bartak NA, Wallace MJ, Murthy R. Liver abscess after inadvertent transhepatic transgression during percutaneous fluoroscopy-guided gastrostomy. *Clin Radiol* 63(6):731-735, 6/2008. e-Pub 11/2007. PMID: 18455567.
9. Wang GR, Ensor JE, Gupta S, Hicks ME, **Tam AL**. Bronchial artery embolization for the management of hemoptysis in oncology patients: Utility and prognostic factors. *J Vasc Interv Radiol* 20(6):722-729, 6/2009. e-Pub 5/2009. PMID: 19406667.
10. **Tam A**, Mohamed A, Pfister M, Rohm E, Wallace MJ. C-arm cone beam computed tomographic needle path overlay for fluoroscopic-guided placement of translumbar central venous catheters. *Cardiovasc Intervent Radiol* 32(4):820-824, 7/2009. PMID: 19123029.
11. **Tam A**, Ensor JE, Snyder H, Gupta S, Durand JB, Wallace MJ. Image-guided drainage of pericardial effusions in oncology patients. *Cardiovasc Intervent Radiol* 32(6):1217-1226, 11/2009. e-Pub 5/2009. PMID: 19472002.
12. Singal AK, Dekovich AA, **Tam AL**, Wallace MJ. Percutaneous transesophageal gastrostomy tube placement: An alternative to percutaneous endoscopic gastrostomy in patients with intra-abdominal metastasis. *Gastrointest Endosc* 71(2):402-406, 2/2010. PMID: 20152318.
13. Avritscher R, Krishnamurthy S, Ensor J, Gupta S, **Tam A**, Madoff DC, Murthy R, Hicks ME, Wallace MJ. Accuracy and sensitivity of computed tomography-guided percutaneous needle biopsy of pulmonary hilar lymph nodes. *Cancer* 116(8):1974-80, 4/2010. e-Pub 2/2010. PMID: 20151422.
14. **Tam AL**, Mohamed A, Pfister M, Chinndurai P, Rohm E, Hall AF, Wallace MJ. C-Arm Cone Beam Computed Tomography Needle Path Overlay for Fluoroscopic Guided Vertebroplasty. *Spine (Phila Pa 1976)* 35(10):1095-9, 5/2010. e-Pub 2/2010. PMID: 20139803.
15. Gupta S, Bedikian AY, Ahrar J, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, **Tam A**, Hwu P. Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors. *Am J Clin Oncol* 33(5):474-80, 10/2010. e-Pub 11/2009. PMID: 19935383.
16. Ahrar J, Gupta S, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, **Tam A**, Hwu P, Bedikian AY. Response, survival and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma. *Cancer Invest* 29(1):49-55, 1/2011. PMID: 21166498.
17. **Tam A**, Singh P, Ensor JE, Carter K, Hicks ME, Wallace MJ, Gupta S. Air travel following biopsy related pneumothorax: Is it safe to fly? *J Vasc Interv Radiol* 22(5):595-602, 5/2011.
18. **Tam A**. Cancer remains the second most common cause of death in the United States, accounting for nearly 1 of every 4 deaths, introduction. *Tech Vasc Interv Radiol* 14(3):109, 9/2011. PMID: 21767776.
19. Odisio BC, **Tam AL**, Avritscher R, Gupta S, Wallace MJ. CT-guided adrenal biopsy: comparison of ipsilateral decubitus versus prone patient positioning for biopsy approach. *Eur Radiol* 22(6):1233-9, 6/2012. e-Pub 1/2012. PMID: 22227794.
20. Kobayashi K, Ozkan E, **Tam A**, Ensor J, Wallace MJ, Gupta S. Preoperative embolization of spinal tumors: variables affecting intraoperative blood loss after embolization. *Acta Radiol* 53(8):935-42, 10/2012. e-Pub 8/2012. PMID: 22927661.



21. Overman MJ, Modak J, Kopetz S, Murthy R, Yao JC, Hicks ME, Abbruzzese JL, **Tam AL**. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? *J Clin Oncol* 31(1):17-22, 1/2013. e-Pub 11/2012. PMID: 23129736.
22. Shaw C, Bassett RL, Fox PS, Schmeler KM, Overman MJ, Wallace MJ, Gupta S, **Tam A**. Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites. *Ann Surg Oncol* 20(2):497-505, 2/2013. e-Pub 9/2012. PMID: PMC4262403.
23. **Tam AL**, Kim ES, Lee JJ, Ensor JE, Hicks ME, Tang X, Blumenschein GR, Alden CM, Erasmus JJ, Tsao A, Lippman SM, Hong WK, Wistuba II, Gupta S. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. *J Thorac Oncol* 8(4):436-42, 4/2013. PMID: 23442309.
24. Philip A, Gupta S, Ahrar K, **Tam AL**. A spectrum of nerve injury after thermal ablation: A report of four cases and review of the literature. *Cardiovasc Intervent Radiol* 36(5):1427-1435, 10/2013. e-Pub 10/2012. PMID: 23070103.
25. Sabir SH, Armstrong R, Elting LS, Wallace MJ, Gupta S, **Tam AL**. Early initiation of enteral feeding in cancer patients after outpatient percutaneous fluoroscopy-guided gastrostomy catheter placement. *J Vasc Interv Radiol* 25(4):618-22, 4/2014. PMID: 24674218.
26. **Tam AL**, Abdelsalam ME, Gagea M, Ensor JE, Moussa M, Ahmed M, Goldberg SN, Dixon K, McWatters A, Miller JJ, Srimathveeravalli G, Solomon SB, Avritscher R, Wallace MJ, Gupta S. Irreversible electroporation of the lumbar vertebrae in a porcine model: Is there clinical-pathologic evidence of neural toxicity? *Radiology* 272(3):709-719, 9/2014. e-Pub 4/2014. PMID: 24766034.
27. **Tam AL**, Melancon MP, Ensor J, Liu Y, Dixon K, McWatters A, Gupta S. Rabbit hepatic arterial anatomy variations: Implications on experimental design. *Acta Radiol* 55(10):1226-33, 12/2014. e-Pub 11/2013. PMID: PMC4262404.
28. Odisio BC, Ashton A, Yan Y, Wei W, Kaseb A, Wallace MJ, Vauthey JN, Gupta S, **Tam AL**. Transarterial hepatic chemoembolization with 70-150  $\mu$ m drug-eluting beads: assessment of clinical safety and liver toxicity profile. *J Vasc Interv Radiol* 26(7):965-71, 7/2015. e-Pub 6/2015. PMID: PMC4484796.
29. **Tam AL**, Ensor JE, Zvavanjanja RC, Philip A, Abdelsalam ME, Huang SY, Gupta S, Jones AK. JOURNAL CLUB: Standardizing CT-guided biopsy procedures: patient dose and image noise. *AJR Am J Roentgenol* 205(4):W390-9, 10/2015. PMID: 26397346.
30. Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, **Tam A**, Hong WK, Ellis LM, Abbruzzese J, Overman MJ. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. *J Clin Oncol* 33(31):3583-90, 11/2015. e-Pub 8/2015. PMID: 26304898.
31. Kuban JD, **Tam AL**, Huang SY, Ensor JE, Philip AS, Chen GJ, Ahrar J, Murthy R, Avritscher R, Madoff DC, Mahvash A, Ahrar K, Wallace MJ, Nachiappan AC, Gupta S. The effect of needle gauge on the risk of pneumothorax and chest tube placement after percutaneous computed tomographic (CT)-guided lung biopsy. *Cardiovasc Intervent Radiol* 38(6):1595-602, 12/2015. e-Pub 4/2015. PMID: 25920917.
32. **Tam AL**, Lim HJ, Wistuba II, Tamrazi A, Kuo MD, Ziv E, Wong S, Shih AJ, Webster RJ, Fischer GS, Nagrath S, Davis SE, White SB, Ahrar K. Image-guided biopsy in the era of personalized cancer care: proceedings from the Society of Interventional Radiology Research Consensus Panel. *J Vasc Interv Radiol* 27(1):8-19, 1/2016. e-Pub 11/2015. PMID: 26626860.
33. Weksberg DC, Yang JN, **Tam AL**, Li J, Wang XA, Zhao Z, et al. Prospective validation of treatment accuracy using implanted fiducial markers for spinal stereotactic body radiation therapy. *J Radiosurg SBRT* 4(1):7-14, 1/2016.
34. **Tam AL**, Melancon MP, Abdelsalam M, Figueira TA, Dixon K, McWatters A, et al. Imaging intratumoral nanoparticle uptake after combining nanoembolization with various ablative therapies in hepatic VX2 rabbit tumors. *J Biomed Nanotechnol* 12(2):296-307, 2/2016. PMID: 27305763.
35. **Tam AL**, Figueira TA, Gagea M, Ensor JE, Dixon K, McWatters A, Gupta S, Fuentes DT. Irreversible electroporation in the epidural space of the porcine spine: effects on adjacent structures. *Radiology*:152688. e-Pub 6/2016. PMID: 27266723.

36. Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, **Tam AL**, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE-2 Study: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer. *J Clin Oncol*. e-Pub 8/2016. PMID: 27480147.
37. Ahrar JU, Gupta S, Ensor JE, Mahvash A, Sabir SH, Steele JR, McRae SE, Avritscher R, Huang SY, Odisio BC, Murthy R, Ahrar K, Wallace MJ, **Tam AL**. Efficacy of a self-expanding tract sealant device in the reduction of pneumothorax and chest tube placement rates after percutaneous lung biopsy: A matched controlled study using propensity score analysis. *Cardiovasc Intervent Radiol* 40(2):270-276, 2/2017. e-Pub 11/2016. PMID: PMC5215969.
38. Gupta N, Patel A, Ensor J, Ahrar K, Ahrar J, **Tam A**, Odisio B, Huang S, Murthy R, Mahvash A, Avritscher R, McRae S, Sabir S, Wallace M, Matin S, Gupta S. Multiple renal artery pseudoaneurysms in patients undergoing renal artery embolization following partial nephrectomy: correlation with RENAL nephrometry scores. *Cardiovasc Intervent Radiol* 40(2):202-209, 2/2017. e-Pub 9/2016. PMID: 27681271.
39. Rostas J, **Tam A**, Sato T, Kelly L, Tatum C, Scoggins C, McMasters K, Martin RCG. Imaged-guided trans-arterial chemo-embolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for un-resectable hepatic metastases from melanoma: technique and outcomes. *Cardiovasc Intervent Radiol*. e-Pub 5/2017. PMID: 28508253.
40. Odisio BC, Cox VL, Faria SC, Yamashita S, Shi X, Ensor J, Jones AK, Mahvash A, Gupta S, **Tam AL**, Vauthey JN, Murthy R. Prognostic value of incidental hypervascular micronodules detected on cone-beam computed tomography angiography of patients with liver metastasis. *Eur Radiol*. e-Pub 5/2017. PMID: 28484824.
41. Rostas JW, **Tam AL**, Sato T, Scoggins CR, McMasters KM, Martin RCG. Health-related quality of life during trans-arterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for unresectable hepatic metastases from ocular melanoma. *Am J Surg*. e-Pub 7/2017. PMID: 28754534.
42. Parseghian C, Raghav K, Wolff RA, Ensor JE, Yao JC, Ellis LM, **Tam A**, Overman MJ. Under-reporting of Research Biopsies from Clinical Trials in Oncology. *Clin Cancer Res*. e-Pub 7/2017. PMID: 28754815.
43. Litwin RJ, Huang SY, Sabir SH, Hoang QB, Ahrar K, Ahrar J, **Tam AL**, Mahvash A, Ensor JE, Kroll M, Gupta S. Impact of an inferior vena cava filter retrieval algorithm on filter retrieval rates in a cancer population. *J Vasc Surg Venous Lymphat Disord* 5(5):689-697, 9/2017. PMID: 28818223.
44. Gardner CS, Ensor JE, Ahrar K, Huang SY, Sabir SH, Tannir NM, Lewis VO, **Tam AL**. Cryoablation of bone metastases from renal cell carcinoma for Local tumor control. *J Bone Joint Surg Am* 99(22):1916-1926, 11/2017. PMID: 29135665.
45. Melancon MP, Appleton Figueira T, Fuentes DT, Tian L, Qiao Y, Gu J, Gagea M, Ensor JE, Muñoz NM, Maldonado KL, Dixon K, McWatters A, Mitchell J, McArthur M, Gupta S, **Tam AL**. Development of an electroporation and nanoparticle-based therapeutic platform for bone metastases. *Radiology* 286(1):161721, 1/2018. e-Pub 8/2017. PMID: 28825892.
46. Ahrar K, Sabir SH, Yevich SM, Sheth RA, Ahrar JU, **Tam AL**, Stafford JR. MRI guided interventions in musculoskeletal system. *Top Magn Reson Imaging* 27(3):129-139, 6/2018. PMID: 29870465.
47. Sheth RA, Perkins N, Dondossola E, Subudhi SK, Gade TP, **Tam AL**. Patient-derived xenograft tumor models: overview and relevance to IR. *J Vasc Interv Radiol* 29(6):880-882.e1, 6/2018. PMID: 29798759.
48. Ferry-Galow KV, Datta V, Makhlof HR, Wright J, Wood BJ, Levy E, Pisano ED, **Tam AL**, Lee SI, Mahmood U, Rubinstein LV, Doroshow JH, Chen AP. What can be done to improve research biopsy quality in oncology clinical trials? *J Oncol Pract:JOP*1800092. e-Pub 10/2018. PMID: 30285529.
49. Chehab MA, Thakor AS, Tulin-Silver S, Connolly BL, Cahill AM, Ward TJ, Padia SA, Kohi MP, Midia M, Chaudry G, Gemmete JJ, Mitchell JW, Brody L, Crowley JJ, Heran MKS, Weinstein JL, Nikolic B, Dariushnia SR, **Tam AL**, Venkatesan AM. Adult and pediatric antibiotic prophylaxis during vascular and IR procedures: A Society of Interventional

- Radiology practice parameter update endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology. *J Vasc Interv Radiol* 29(11):1483-1501.e2, 11/2018. e-Pub 9/2018. PMID: 30274857.
50. Parseghian CM, **Tam AL**, Yao J, Ensor J, Ellis LM, Raghav K, Overman MJ. Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. *JAMA Oncol*. e-Pub 11/2018. PMID: 30383128.
  51. Nelson DB, **Tam AL**, Mitchell KG, Rice DC, Mehran RJ, Sepesi B, Antonoff MB, Vaporciyan AA, Hofstetter WL. Local Recurrence After Microwave Ablation of Lung Malignancies: A Systematic Review. *Ann Thorac Surg*:Wayne L. Hofstetter. e-Pub 11/2018. PMID: 30508527.
  52. Casal RF, Sarkiss M, Jones AK, Stewart J, **Tam A**, Grosu HB, Ost DE, Jimenez CA, Eapen GA. Cone beam computed tomography-guided thin/ultrathin bronchoscopy for diagnosis of peripheral lung nodules: a prospective pilot study. *J Thorac Dis* 10(12):6950-6959, 12/2018. PMID: PMC6344689.
  53. Krishnamurthy S, Ban K, Shaw K, Mills G, Sheth R, **Tam A**, Gupta S, Sabir S. Confocal fluorescence microscopy platform suitable for rapid evaluation of small fragments of tissue in surgical pathology practice. *Arch Pathol Lab Med* 143(3):305-313, 3/2019. e-Pub 10/2018. PMID: 30376375.
  54. McWilliams JP, Bilhim TA, Carnevale FC, Bhatia S, Isaacson AJ, Bagla S, Sapoval MR, Golzarian J, Salem R, McClure TD, Kava BR, Spies JB, Sabharwal T, McCafferty I, **Tam AL**. Society of Interventional Radiology Multisociety Consensus Position Statement on Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: From the Society of Interventional Radiology, the Cardiovascular and Interventional Radiological Society of Europe, Société Française de Radiologie, and the British Society of Interventional Radiology: Endorsed by the Asia Pacific Society of Cardiovascular and Interventional Radiology, Canadian Association for Interventional Radiology, Chinese College of Interventionalists, Interventional Radiology Society of Australasia, Japanese Society of Interventional Radiology, and Korean Society of Interventional Radiology. *J Vasc Interv Radiol*. e-Pub 3/2019. PMID: 30926185.
  55. Davidson JC, Rahim S, Hanks SE, Patel LJ, **Tam AL**, Walker TG, Weinberg I, Wilkins LR, Sarode R. Society of Interventional Radiology Consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guide interventional - Part I: Review of anticoagulation agents and clinical considerations: Endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology. *J Vasc Interv Radiol*. In Press.
  56. Patel IJ, Rahim S, Davidson JC, Hanks SE, ~~Tam AL~~, Walker TG, Wilkins LR, Sarode R, Weinberg I. Society of Interventional Radiology Consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guide interventional - Part II: Recommendations: Endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology. *J Vasc Interv Radiol*. In Press.

[56-57.](#)

#### Invited Articles

1. **Tam A**, Ahrar K. Palliative interventions for pain in cancer patients. *Semin Intervent Radiol* 24(4):419-429, 12/2007. PMID: PMC3037251.
2. Casal RF, **Tam AL**, Eapen GA. Radiofrequency ablation of lung tumors. *Clin Chest Med* 31(1):151-163, 3/2010. PMID: 20172441.
3. Nazario J, **Tam AL**. Ablation of bone metastases. *Surg Oncol Clin N Am* 20(2):335-368, 4/2011. PMID: 21377588.
4. Nazario J, Hernandez J, **Tam AL**. Thermal ablation of painful bone metastases. *Tech Vasc Interv Radiol* 14(3):150-159, 9/2011. PMID: 21767782.
5. Sabir SH, **Tam AL**. Percutaneous image-guided biopsy of the spleen. *Dig Dis Interv* 2(2):101-105, 7/2018.
6. Yevich S, Sheth R, Ojeshina O, **Tam A**. Interventional radiology techniques for the management of painful bone metastases. *J Radiol Nurs* 37:90-97, 2018.

#### Editorials

1. **Tam AL**, Findeiss L, Dake MD, Collins JD, Liu RW, Haskal ZJ, Vedantham S, Sedory SE, Marx MV. Standards 2.0: Methodology Update. *J Vasc Interv Radiol*. e-Pub 9/2018. PMID: 30274857.

#### Other Articles

1. **Tam A**. Cancer remains the second most common cause of death in the United States, accounting for nearly 1 of every 4 deaths, Introduction. *Tech Vasc Interv Radiol* 14(3):150-159, 9/2011. PMID: 21767776.
2. Liu DM, Gandhi R, **Tam AL**. Colorectal hepatic metastasis: The past, present, and future role of liver-directed therapy. *Endovascular Today*:63-74, 10/2015.
3. Sabir SH, Caldwell KL, Moor BS, **Tam A**. Percutaneous thermal ablation techniques for the treatment of musculoskeletal metastases. *Orthopaedic Knowledge Online Journal* 13(11), <http://orthoportal.aaos.org/oko/default.aspx#tab1>, 11/2015.
4. **Tam A**. Image-guided biopsy in the era of personalised cancer care. *Interventional News*. e-Pub 5/2016.
5. Ahrar K, Sabir S, **Tam AL**, Suh R, Littrup PJ, Dupuy DE. What would world experts do under challenging and tricky encounters? Lung Ablation. *Endovascular Today* 15(9):77-80, 2016.
6. Kuban JD, **Tam AL**. Ensuring a good death: pain management and palliative procedures in the oncology patient. *Endovascular Today* 16(10):97-102, 2017.

#### Abstracts

1. Appleton FT, Fuentes D, McWatters A, Dixon K, Gagea MI, **Tam A**. Determining the energy threshold for irreversible electroporation of the spinal cord with mathematical modeling. *J Vasc Interv Radiol* 26(2S):S118, 2/2015.
2. Patel R, Lin B, Ahrar J, **Tam A**, Ahrar K. Enhancing the care of cancer patients with ureteral strictures managed with percutaneous nephrostomy tubes. *J Clin Oncol* 34(3\_suppl):e264-e276, 1/2016. PMID: 28151284.
3. Muñoz NM, Minhaj AA, Galloway-Peña JR, Melancon MP, Shelburne SA, **Tam AL**. Irreversible electroporation for control of osteomyelitis caused by *Staphylococcus aureus*. 2016 Society of Interventional Radiology Annual Scientific Meeting, 3/2016.
4. Odisio BC, Cox VL, Mahvash A, Xiao S, Ensor J, Wallace MJ, Jones AK, Gupta S, **Tam AL**, Murthy R, Faria SC. Incidentally-found miliary liver lesions on Cone-beam CT angiography: higher risk for metastatic hepatic disease progression. Global Academic Program (GAP) MD Anderson, MDAnderson Cancer Center, 4/2016.
5. Odisio BC, Figueira TA, Sabir SH, Wei W, Abdelsalam ME, Huang SY, **Tam AL**, Mahvash A, Gupta S, Wallace MJ, Vauthey JN, Kaseb AO. Large single hepatocellular carcinomas treated with transarterial chemoembolization: In which BCLC Stage patients should be allocated? European Association for the Study of the Liver Conference, 4/2016.
6. Swigost A, **Tam AL**, Liu D, Wasan E, Kos S, Melancon MP. Creation of a nanoparticle drug delivery platform with lipiodol, doxorubicin and irinotecan: method and performance characteristics. GEST, New York, NY, 5/2016.
7. Frisch B, Matthies P, Grosser O, **Tam AL**, Kappadath S, Navab N. Interventional nuclear imaging for SIRT-a phantom study. *J Nucl Med* 57(2):304, 5/2016.
8. Gardner S, Ensor J, Huang SY, Ahrar K, Sabir SH, Gupta S, Lewis VO, **Tam AL**. Cryoablation for local disease control of renal cell carcinoma bone metastases. World Conference on Interventional Oncology, 6/2016.
9. Odisio BC, Cox VL, Mahvash A, Xiao S, Ensor J, Wallace MJ, Jones AK, Gupta S, **Tam AL**, Murthy R, Faria SC. Incidentally-found miliary liver lesions on Cone-beam CT angiography: higher risk for metastatic hepatic disease progression. 2016 World Conference on Interventional Oncology, 6/2016.
10. **Tam A**, Melancon M, Appleton-Figueira T, Tian L, Ensor J, Maldonado K, Dixon K, McWatters A, McArthur M, Gupta S. Developing an electroporation and nanoparticle-based therapeutic platform for bone metastases. Radiological Society of North America 102nd Scientific Assembly and Annual Meeting, 11/2016.

11. Matheus P, **Tam A**, Sheth RA, Gupta S, Sabir S. Safety and accuracy of percutaneous image-guided spleen biopsy. Proceedings of the 42nd Annual Meeting of the Society of Interventional Radiology, 3/2017.
12. Harmoush S, Dimayuga MB, **Tam A**, Odisio B, Sheth RA, Ensor J, Gupta S, Huang S. Safety and efficacy of percutaneous venting gastrostomy tubes for malignant bowel obstruction and ascites. Proceedings of the 42nd Annual Meeting of the Society of Interventional Radiology, 3/2017.
13. Linch F, Ahrar K, Ruiz JR, Sabir SH, **Tam AL**. Value of adrenergic blockade in preventing hypertensive crisis during ablation of adrenal masses. Proceedings of the 42nd Annual Meeting of the Society of Interventional Radiology, 3/2017.
14. Parseghian CM, Raghav K, Yao J, Ellis LM, **Tam A**, Overman MJ. Under-reporting of research biopsies in clinical trials in oncology. Proceedings of the 110th Annual Meeting of the American Association for Cancer Research, 4/2017.
15. **Tam AL**, Papadimitrakopoulou V, Wistuba I, Lee JJ, Ensor JE, Kim ES, Kalhor N, Blumenschein GR, Tsao AS, Heymach JV, Herbst RS, Hicks ME, Hong WK, Gupta S. A team-science approach to support personalized cancer care: role and value of interventional radiology in clinical trials. Radiological Society of North America 103rd Scientific Assembly and Annual Meeting, 11/2017.
16. Yevich S, Chintalapani G, Sheth RA, Huang SY, Sabir S, **Tam AL**. Imaging optimization by twin-beam dual energy computed tomography to improve visualization of therapeutic iceball margins during cryoablation of musculoskeletal malignancies. Radiological Society of North America 103rd Scientific Assembly and Annual Meeting, 11/2017.
17. Litwin RJ, Charleston SC, **Tam AL**, Sheth RA, Briones MC, Gupta S, Huang SY. Safety and efficacy of percutaneous transesophageal gastric tubes for decompression of malignant bowel obstruction. Radiological Society of North America 103rd Scientific Assembly and Annual Meeting, 11/2017.
18. Yevich S, **Tam A**. Integrated fluoroscopy-CT units: changing the IR treatment potential for challenging musculoskeletal metastases. 10th Annual Symposium on Clinical Interventional Oncology, 2/2018.
19. Beardsley A, Sheth R, Haydu L, Gardner J, Kuban J, **Tam A**, et al. Locoregional therapy for liver metastases in uveal melanoma: improvements in progression free survival and predictors of response. Supplement to JVIR, Society of Interventional Radiology 2018 Annual Scientific Meeting Program 29(4S):S220 (#523), A Beardsley1, R Sheth2, L Haydu2, J Gardner2, J Ku, 4/2018.
20. Khan M, Daileida T, Sabir S, **Tam A**, Gupta S, Sheth S, Sheth R. Population-based analysis of percutaneous liver biopsies: complications, utilization, and predictors of outcomes. Supplement to JVIR, Society of Interventional Radiology 2018 Annual Scientific Meeting Program 29(4S) (#1028), M Khan1, T Daileida2, S Sabir1, A Tam1, S Gupta1, S, 4/2018.
21. Khan M, Daileida T, Sabir S, **Tam A**, Gupta S, Sheth S, Sheth R. Population-based analysis of percutaneous renal biopsies: complications, utilization and predictors of outcomes. Proceedings of the 43rd Annual Meeting of the Society of Interventional Radiology 29(4S):S211 (#501), 4/2018.
22. Pohlen M, Kuban J, Murphy R, Sheth R, McRae S, Ahrar J, **Tam A**, Gupta S. Safety and diagnostic utility of percutaneous transcaval retroperitoneal biopsies. Supplement to JVIR, Society of Interventional Radiology 2018 Annual Scientific Meeting Program 29(4S):S284 (#691), 4/2018.
23. Khan M, Daileida T, Kuban J, Yevich S, Huang S, Sabir S, Ahrar K, **Tam A**, Gupta S, Sheth S, Sheth R. The influence of IVC filters on the rate of pulmonary embolism in patients with deep venous thrombosis: a population-based study. Supplement to JVIR, Society of Interventional Radiology 2018 Annual Scientific Meeting Program 29(4S):S26 (#51), 4/2018.
24. Niekamp A, Khan M, Daileida T, Kuban J, Yevich S, Miller E, **Tam A**, Gupta S, Sheth S, Sheth R. Transjugular intrahepatic portosystemic improves outcomes in cirrhotic patients with variceal bleeding: a population-based analysis. Supplement to JVIR, Society of Interventional Radiology 2018 Annual Scientific Meeting Program 29(4S):S260 (#625), 4/2018.
25. Niekamp A, Khan M, Daileida T, Kuban J, Yevich S, Miller E, **Tam A**. Transjugular intrahepatic portosystemic shunting reduces paracentesis rates in patients with cirrhosis and

- ascites: a population-based analysis. Supplement to JVIR, Society of Interventional Radiology 2018 Annual Scientific Meeting Program 29(4S):S121 (#282), 4/2018.
26. Smuclovsky E, Lin EY, Chintalapani G, Sheth R, Huang S, Sabir S, **Tam A**, Yevich SY. Utility of dual-energy CT to improve visualization of the therapeutic iceball during CT-guided cryoablation of musculoskeletal metastases. European Conference on Interventional Oncology. e-Pub 4/2018.
  27. Connors T, Sabir S, **Tam A**, Ahrar K, Sheth R, Gupta S, Steele J. Value of performing outpatient CT-guided percutaneous lung biopsy at a large, tertiary care center after unsuccessful outside hospital biopsy attempt. Supplement to JVIR, Society of Interventional Radiology 2018 Annual Scientific Meeting Program 29(4S):S263 (#608), 4/2018.
  28. Donato F, Ahrar K, Abdelsalam M, **Tam A**, Sheth R. Combined transarterial renal embolization and percutaneous image-guided renal ablation for treatment of T1B and central renal cell carcinomas in patients with high surgical risk. Supplement to JVIR 30(3S):S151 (#343), 3/2019.
  29. Jones AK, Kisiel IM, Rong J, **Tam AL**. Comparison of measured peak skin dose to scanner-reported dose indices during CT-guided interventions. Supplement to JVIR 30(3S):S163 (#369), 3/2019.
  30. Munoz N, Dixon K, Williams M, Maldonado K, Dupuis C, Rashid A, Yevich S, **Tam A**. Development of a transplantable colon adenocarcinoma model in the Buffalo rat. Supplement to JVIR 30(3S):S262 (#609), 3/2019.
  31. Munoz N, Dupuis C, Williams M, Dixon K, Maldonado K, Murthy R, **Tam A**, Avritscher R, Cressman E, Sheth RA. Intratumoral delivery of immunotherapeutics: optimizing drug delivery for improved treatment efficacy. Supplement to JVIR 30(3S):S142 (#322), 3/2019.
  32. Jones C, Ahrar K, **Tam A**, Sabir S. Local control and overall survival after cryoablation of adrenal malignancies. 119th ARRS Annual Meeting, 5/2019.

#### Book Chapters

1. **Tam AL**. Mediastinal Biopsy. In: Gervais DA ed. *Interventional Radiology Procedures in Biopsy and Drainage*. Ed(s) DA Gervais. Springer, 2010.
2. **Tam AL**. Adrenal Gland Biopsy. In: *Percutaneous Image-Guided Biopsy*. Ed(s) K Ahrar, S Gupta. Springer, 213-225, 2014.
3. Sabir SH, **Tam AL**. Interventional Radiology Procedures in Renal Cell Carcinoma. In: *Renal Cell Carcinoma (Oxford American Oncology Library)*. Ed(s) N. Tann. Oxford University Press, 2014.
4. Abdelsalam M, Kobayashi K, Avritscher R, Gupta S, **Tam AL**. Intra-Arterial Procedures for the Musculoskeletal System. In: *Clinical Interventional Oncology, First*. Ed(s) ST Kee, R Murthy, DC Madoff. Elsevier: Philadelphia, 342-354, 2014. PMID: 978-1-4557-1221-2.
5. Tutton SM, Zvavanjanja RC, **Tam AL**. Musculoskeletal Interventions for Benign Bone Lesions. In: *Clinical Interventional Oncology, First*. Ed(s) ST Kee, R Murthy, DC Madoff. Elsevier: Philadelphia, 302-319, 2014.
6. **Tam AL**. Spleen Biopsy. In: *Percutaneous Image-Guided Biopsy*. Ed(s) K Ahrar, S Gupta. Springer: New York, 207-212, 2014.

#### Books (edited and written)

1. **Tam AL**. Ed(s) ST Kee, R Murthy, DC Madoff. *Musculoskeletal Oncology*. In: *Clinical Interventional Oncology*. In: *MSK Oncology, First*. Elsevier: Philadelphia, 2014.

#### Letters to the Editor

1. Adams PL, **Tam AL**, Amini B, Hoang QB, Lewis VO, Huang SY. Percutaneous cryoablation of scapular metastasis associated with iatrogenic injury to the suprascapular, subscapular, and axillary nerves. *J Vasc Interv Radiol* 26(8):1247-9, 8/2015. PMID: 26210248.

#### Manuals, Teaching Aids, Other Teaching Publications

1. **Tam AL**. Society of Interventional Radiology 34<sup>th</sup> Annual Scientific Meeting Workshop Book: Portal Vein Embolization, 3/2009.
2. Hwang G, Sabir S, Wells S, **Tam AL**. Workshop Book: Renal Cell Carcinoma: Ablation, Embolization and Other Therapies. Society of Interventional Radiology 40th Annual Scientific Meeting, 3/2015.

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

3. Jennings J, **Tam AL**, Schmitz JJ, Kelekis A, Kurup AN. Workshop Book: MSK Intervention I Pearls and FAQs. Society of Interventional Radiology 41st Annual Scientific Meeting, 4/2016.
- 4.1. Munk PL, Kurup AN, **Tam AL**, Deschamps F. Workshop Book: MSK Intervention I: Basic procedures the IR should know. Society of Interventional Radiology 42nd Annual Scientific Meeting, 4/2017.

**Other Publications**

N/A

**EDITORIAL AND REVIEW ACTIVITIES**

**Editor/Service on Editorial Board(s)**

Member, Interventional Radiology News Editorial Board, Society of Interventional Radiology, 2009-2017

Guest Editor, Issue of Techniques in Vascular and Interventional Radiology, 2011

**Member of Editorial Review Board**

N/A

**Journal Reviewer**

Reviewer, Journal of Vascular and Interventional Radiology, 2007-present

Reviewer, Radiographics, 2010-present

Reviewer, Radiology, 2016-present

**Other Editorial and Review Activities**

N/A

**TEACHING**

**Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center**

**Formal Teaching**

**Courses Taught**

Lecturer, Annual Interventional Radiology Board Review  
2007-2013

Lecturer, Advanced Interventional Techniques in Thoracic Malignancies An intensive hands-on-course. RFA: Role in Lung Cancer  
2008

Lecturer, Interventional Pulmonology in Cancer Patients: IR: Role in Lung Tumors  
2009-2011  
2015

Proctor, Interventional Pulmonology in Cancer Patients: Tunneled Pleural Catheter and Chest Tube Insertion Station  
2010-2015  
2016-2018

Lecturer, Department of Genitourinary Medical Oncology Course on Renal Cell Carcinoma, The Role of IR in the Management of Patients with Metastatic RCC  
2011

Lecturer, Thermal Ablation in Lung: Current Status, Interventional Pulmonology in Cancer Patients 2012 Conference  
2012

Percutaneous Ablation: Role in Thoracic Malignancies, Interventional Pulmonology in Cancer Patients: An Intensive Hands-on Course  
2/2013

Image-guided Tissue Acquisition, MD Anderson Clinical Trials Methods & Design Workshop for Junior Faculty  
3/2014

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

5/2015

MD Anderson-Endocare Inc. Bone/Musculoskeletal Cryoablation Preceptorship  
4/2019

**Training Programs**

Lecturer, Endoleaks/Repair and Aortic Fenestration, The University of Texas  
MD Anderson Cancer Center Interventional Radiology Fellowship Program  
2007-2012

Lecturer, Spine Embolization, The University of Texas MD Anderson Cancer Center  
Interventional Radiology Fellowship Program  
2010  
2012-2018

**Other Formal Teaching**

Lecturer, Breast Medical Oncology Noon Conference: Thermal Ablation of Bone:  
Palliative Intervention in the Cancer Patient  
2007

Lecturer, Breast Medical Oncology Noon Conference: Local Management of Patients with  
Metastatic Breast Cancer with Liver Dominant Disease  
2007

Lecturer, Institutional Grand Rounds: Multidisciplinary Management of Spinal Tumors  
"Spine Interventions in the Oncology Patient  
2008

Lecturer, Melanoma Translational Research Meeting: Drug Eluting Beads for  
Chemoembolization  
2008

Lecturer, Palliative Care Noon Conference: Thermal Ablation of Bone: Palliative  
Intervention in the Cancer Patient  
2008

Lecturer, Internal Medicine Challenging Cases Presentation - Common Interventional  
Radiology Procedures for the GI Oncology Patient  
2010

Lecturer, Melanoma Medical Oncology Grand Rounds: Locoregional Management of  
Patients with Metastatic Melanoma & Liver Dominant Disease  
2010

Lecturer, Science Day for Lung Cancer Research: Tissue is the Issue: Enabling Patients  
to Pursue Individualized Cancer Therapy  
2010

Speaker, Investigational Cancer Therapeutics Research Team Meeting, The Changing  
Face of Biopsy  
7/2014

Chair, Institutional Grand Rounds, Interventional Radiology in the Management of Bone  
Metastases: Current State and Future Directions  
11/2017

Speaker, Institutional Grand Rounds, MSK Ablation: Future Directions  
11/2017

Speaker, Surgical Oncology Grand Rounds, What's New in Non-Thermal Ablation: IRE  
1/2018

Grand Rounds, Minimizing Patient Risk: Interventional Radiology Perspective  
2/2019



**Supervisory Teaching  
Committees**

**Advisory Committees**

Committee Member, Interventional Radiology Educational Core Group, Fellow  
Candidates, 2007-2012

Member, Interventional Radiology Educational Core Group, Residency Candidates,  
2018-present

**Supervisory Committees**

N/A

**Examining Committees**

N/A

**Direct Supervision**

**Undergraduate and Allied Health Students**

N/A

**Medical Students**

Research Mentor, Research Elective, Asher Philip, 12/2011-5/2012

**Graduate Students**

N/A

**Postdoctoral Research Fellows**

Research Mentor, Dr. Mohamed Elsayed M. Abdelsalam, 2/2011-5/2011

Research Mentor, Dr. Tomas Appleton Figueira, 9/2013-present

**Clinical Residents and Fellows**

Interventional Radiology Fellowship Program, Drs. Adam N. Delu, Jaime L. Abesada-  
Aguet, Scott A. Allison, Scott G. Bryk, 7/2006-6/2007

Interventional Radiology Fellowship Program, Drs. Gin R. Wang, Jorge Taboada,  
Paul G. Selina, Seth Roberts, 7/2007-6/2008

Interventional Radiology Fellowship Program, Drs. Ann Marie Marciel, Hui-Yong  
Chung, Kenneth Bryant, Ryan Armstrong, 7/2008-6/2009

Interventional Radiology Fellowship Program, Drs. Bruno C. Odisio, Efe Ozkan, Javier  
A. Nazario, Niska A. Blevins, Rebecca J. Borders, 7/2009-6/2010

Interventional Radiology Fellowship Program, Drs. Paul D. Bertolino,  
Sendasaperumal N, Sendos, Colette M. Shaw, Mark A. Sultenfuss, John S. Yoo,  
7/2010-6/2011

Interventional Radiology Fellowship Program, Drs. Andrew Baugh, Rodrick  
Zvavanjana, Mohamed Mansour, John Hancock, and William Dawson, 7/2011-6/2012

Interventional Radiology Fellowship Program, Drs. Sadeer Alzubaidi, Sameer Gadani,  
Melissa Hite, Sharjeel Sabir, Timothy Townsend, 7/2012-6/2013

Interventional Radiology Fellowship Program, Drs. Lori Sedrak, Justin Smith, Beau  
Black, Patrick Marcin, 7/2013-6/2014

Interventional Radiology Fellowship Program, Drs. Erika Kashef, Justin Muhlenberg,  
Michael Richter, Paul Hannon, Steven Cooper, Mohamed Abdelsalam, 7/2014-6/2015

The Interventional Radiology Fellowship Program, Drs. Aaron Ashton, Jared  
Christensen, Stephen Dreyer, Ana Maria Pabon-Martinez, Phillip Parmet, Mohamed  
Abdelsalam, 7/2015-6/2016

The Interventional Radiology Fellowship Program, Drs. Andrew Barrow, Bridgid  
Bingham, David Chiao, Rayhan Hai, Randall Heller, Samer Harmoush, 7/2016-6/2017

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

Interventional Radiology Fellowship Program, Drs. Tessa Hudspeth, Kevin Burns, Patrick Hussey, Jason Low, Kenny Sam, Francisco Donato, Tomas Appleton-Figueira, 7/2017-6/2018

Interventional Radiology Fellowship Program, Drs. Garrett Bennett, Roshon Amin, Laura Leonards, Kaiming Wu, Francisco Donato, Ali Baiomy, Nakul Reddy, Nathan Wnuk, 7/2018-6/2019

**Other Supervisory Teaching**

Faculty Mentor for Interventional Radiology Research Program, Dr. Gin R. Wang, 2007-2008

Faculty Mentor for Interventional Radiology Research Program, Dr. Kenneth Bryant, 2008-2009

Faculty Mentor for Interventional Radiology Research Program, Dr. Ryan Armstrong, 2008-2009

Faculty Mentor for Interventional Radiology Research Program, Dr. Paul Bertolino and Dr. Colette Shaw, 2010-2011

Faculty Mentor for Interventional Radiology Research Program, Dr. Rodrick Zvavanjana, 2011-2012

**Teaching Outside Current Institution**

**Formal Teaching**

**Courses Taught**

N/A

**Training Programs**

N/A

**Other Formal Teaching**

Lecturer, UT Radiology Residency Noon Lecture Series, MSK Biopsies and Bone Tumor Interventions, 2016, University of Texas Medical School at Houston  
4/2016

**Supervisory Teaching**

**Committees**

**Advisory Committees**

N/A

**Supervisory Committees**

N/A

**Examining Committees**

N/A

**Direct Supervision**

**Undergraduate and Allied Health Students**

N/A

**Medical Students**

N/A

**Graduate Students**

N/A

**Postdoctoral Research Fellows**

N/A

**Clinical Residents and Fellows**

N/A

**Other Supervisory Teaching**

N/A

## CONFERENCES AND SYMPOSIA

### Organization of Conferences/Symposia (Include chairing session)

International Symposium on Endovascular Therapy: Clinical Interventional Oncology, Hollywood, FL, Moderator, 1/2009

Western Angiographic & Interventional Society 41st Annual Conference, Lake Tahoe, NV, Moderator, 8/2011

Society of Interventional Radiology Hospital Administrator Educational Track, Chicago, IL, Chair, 3/2012

Society of Interventional Radiology 2013 Annual Scientific Meeting, New Orleans, LA, Moderator, Non-Vascular Interventions: Thoracic and Genitourinary Scientific Session, 4/2013

Society of Interventional Radiology 2013 Annual Scientific Meeting, New Orleans, LA, Coordinator, Hospital Administrator Program Welcome and Schedule of the Day, 4/2013

Society of Interventional 2014 Annual Scientific Meeting, Palliative Care Session, San Diego, CA, Virtual Moderator, 3/2014

Western Angiographic and Interventional Society, Tumor Ablation SA-CME Session, Kohala Coast, HI, Moderator, 9/2014

Society of Interventional Radiology 40th Annual Scientific Meeting, Atlanta, GA, Coordinator, In The Clinic Workshop, 3/2015

Society of Interventional Radiology Research Consensus Panel: Image Guided Biopsy in the Era of Personalized Medicine, Washington, DC, Lead Investigator, 6/2015

Western Angiography & Interventional Society 45th Annual Conference, Vancouver, Canada, Program Director, 9/2015

Society of Interventional Radiology Annual Scientific Meeting, Musculoskeletal Intervention I: Basic Procedures the IR Should Know, Case-based Workshop, Vancouver, Canada, Moderator, 4/2016

Western Angiography & Interventional Society 46th Annual Conference, Tumor Ablation SA-CME Session, Poipu Bay, HI, Moderator, 9/2016

The 9th Annual Symposium on Clinical Interventional Oncology, Hollywood, FL, Moderator, 2/2017

Society of Interventional Radiology Annual Scientific Meeting, Basic Science, Ablation Scientific Session, Washington, DC, Moderator, 3/2017

Society of Interventional Radiology Annual Scientific Meeting, Musculoskeletal Intervention I: Basic Procedures the IR Should Know, Case-based Workshop, Washington, DC, Moderator, 3/2017

World Conference on Interventional Oncology, Early Career Program, Part 2, Boston, MA, Moderator, 6/2017

Radiological Society of North America 103rd Scientific Assembly and Annual Meeting, Vascular Interventional (IO-Liver Cancer), Scientific Session, Chicago, IL, Moderator, 11/2017

13th Annual Meeting of the Asia Pacific Society of Cardiovascular and Interventional Radiology, MSK Interventional Oncology (Non-Vascular Intervention Session), Auckland, New Zealand, Moderator, 3/2018

17th Annual Scientific Meeting of CAIR, Interventional Oncology Workshop, Calgary, Canada, Moderator, 5/2018

Western Angiographic & Interventional Society 48th Annual Conference, Non-vascular Interventional Oncology, Maui, HI, Moderator, 10/2018

Spectrum 2018, Immuno Oncology, Miami, FL, Moderator, 11/2018

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

IR & Positive Disruption: The potential impact of high-tech image guided intervention on Global Health. Society of Interventional Radiology Annual Scientific Meeting, Austin, TX, Coordinator/Moderator, 3/2019

SA-CME: Biopsy. Society of Interventional Radiology Annual Scientific Meeting, Austin, TX, Coordinator/Moderator, 3/2019

SS39-Needle in a Haystack (Biopsies). Society of Interventional Radiology Annual Scientific Meeting, Austin, TX, Moderator, 3/2019

#### **Presentations at National or International Conferences**

##### **Invited**

Portal vein embolization: Improving the safety of major hepatic resection, Western Angiographic & Interventional Society, 37<sup>th</sup> Annual CME Conference, Santa Fe, NM, 9/2007

Radiofrequency ablation of bone: Palliative intervention in the cancer patient, Western Angiographic & Interventional Society, 37<sup>th</sup> Annual CME Conference, Santa Fe, NM, 9/2007

Portal venous interventions in the oncology patient, Western Angiographic & Interventional Society, 38<sup>th</sup> Annual CME Conference, Maui, HI, 9/2008

Assessing the safety of air travel following lung biopsy: Interim analysis, Radiological Society of North America 94<sup>th</sup> Scientific Assembly, Chicago, IL, 12/2008

**Tam A**, Taboada J, Snyder H, Gupta S, Durand J, Wallace MJ. Image-guided drainage of pericardial effusion in oncology patients, Radiological Society of North America 94<sup>th</sup> Scientific Assembly and Annual Meeting, Chicago, IL, 12/2008

Nonoperative treatment of liver tumors: What are the best options? Radiological Society of North America 2008 Annual Meeting, Chicago, IL, 12/2008

Spine interventions in the oncology patients, International Symposium on Endovascular Therapy: Clinical Interventional Oncology, Hollywood, FL, 1/2009

C-arm cone beam CT needle path overlay for fluoroscopic guided vertebroplasty, Society of Interventional Radiology 34<sup>th</sup> Annual Scientific Meeting, San Diego, CA, 3/2009

Portal vein embolization, SIR 34<sup>th</sup> Annual Scientific Meeting, Tampa, FL, 3/2009

Some like it hot: Arterial delivery of radioactive particles or drug eluting beads for hepatic malignancies, American Society of Clinical Oncology, Orlando, FL, 5/2009

Personalized lung cancer therapy: safety and adequacy of image-guided small-caliber core needle biopsy for evaluation of multiple molecular biomarkers, 13th World Conference on Lung Cancer, San Francisco, CA, 7/2009

C-arm cone beam CT: Non-vascular applications, Western Angiographic & Interventional Society 39th Annual CME Conference, La Jolla, CA, 9/2009

Cryoablation of bone in the oncology patient, Western Angiographic & Interventional Society 39<sup>th</sup> Annual CME Conference, La Jolla, CA, 9/2009

**Tam AL**, Kim ES, Stewart D, Herbst RS, Wistuba II, Hicks ME, Hong WK, Gupta S. Safety and adequacy of image-guided small caliber core needle transthoracic biopsies for evaluation of multiple molecular biomarkers in clinical trials, Radiological Society of North America 2009 Annual Meeting, Chicago, IL, 11/2009

**Tam AL**, Gupta S, Dekovich A, Wallace MJ. Percutaneous fluoroscopic-guided gastrostomy placement in patients with ascites, Radiological Society of North America 2009 Annual Meeting, Chicago, IL, 12/2009

Morbidity and Mortality: Bone ablation, International Symposium on Endovascular Therapy: Clinical Interventional Oncology, Hollywood, FL, 1/2010

Oncologic spine interventions, Symposium on Clinical Interventional Oncology, Hollywood, FL, 1/2010

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

Getting it Done: The Service Contract, Society of Interventional Radiology 35th Annual Scientific Meeting, Tampa, FL, 3/2010

Assessing safety of air travel following biopsy related pneumothorax, Western Angiographic & Interventional Society, 40th Annual CME Conference, Lanai, HI, 9/2010

Ablation for bone tumors: current status, International Symposium on Endovascular Therapy: Clinical Interventional Oncology, Miami, FL, 1/2011

Morbidity and Mortality: Renal and bone tumors, International Symposium on Endovascular Therapy: Clinical Interventional Oncology, Miami, FL, 1/2011

Oncologic spine interventions, including a look at plasma-mediated co-ablation in conjunction with vertebroplasty, International Symposium on Endovascular Therapy: Clinical Interventional Oncology, Miami, FL, 1/2011

Ablation therapy in benign MSK tumors: Local control of metastatic disease - Taking it beyond liver and lung, 36th Annual Society of Interventional Radiology Annual Scientific Meeting, Chicago, IL, 3/2011

Musculoskeletal oncologic procedures refresher course, Radiological Society of North America 97th Scientific Assembly and Annual Meeting, Chicago, IL, 11/2011

IR: A Case of Value Creation from MD Anderson Cancer Center, Society of Interventional Radiology 2012 Annual Meeting, Chicago, IL, 3/2012

Radiofrequency ablation: lung treatment as good as liver? 17th World Congress for Bronchology and Interventional Pulmonology and 17th World Congress for Bronchoesophagology, Cleveland, OH, 6/2012

Drug eluting beads in intra-arterial therapy: hype or home run, 11th Oncology Update: Advances and Controversies, Steamboat, CO, 1/2013

Local control of metastatic disease: taking it beyond the liver, Melanoma Research Foundation 2nd Annual CURE OM Eyes on a Cure: Patient and Caregiver Symposium, Houston, TX, 3/2013

Bone and Soft Tissue Ablation - What Patients/What Modality, Society of Interventional Radiology 2013 Annual Scientific Meeting, New Orleans, LA, 4/2013

Feasibility of image-guided transthoracic core needle biopsy in the BATTLE lung trial, Global Academic Programs 2013 Conference, Houston, TX, 4/2013

Film Panel, Society of Interventional Radiology 2013 Annual Scientific Meeting, New Orleans, LA, 4/2013

IR: A Case of Value Creation from MD Anderson Cancer Center, Society of Interventional Radiology 2013 Annual Scientific Meeting, New Orleans, LA, 4/2013

TACE with DEB, Society of Interventional Radiology 2014 Annual Scientific Meeting, San Diego, CA, 3/2014

Case Show, 17th Congresso da Sociedade Brasileira de Radiologia Intervencionista e Cirurgia Endovascular (SOBRICE), Campinas, Sao Paulo, Brazil, 5/2014

IR Collaboration for Oncological Clinical Trials, 17th Congresso da Sociedade Brasileira de Radiologia Intervencionista e Cirurgia Endovascular (SOBRICE), Campinas, Sao Paulo, Brazil, 5/2014

Irreversible Electroporation-Ready for Prime Time? 17th Congresso da Sociedade Brasileira de Radiologia Intervencionista e Cirurgia Endovascular (SOBRICE), Campinas, Sao Paulo, Brazil, 5/2014

Musculoskeletal Lesion Ablation, 17th Congresso da Sociedade Brasileira de Radiologia Intervencionista e Cirurgia Endovascular (SOBRICE), Campinas, Sao Paulo, Brazil, 5/2014

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

Why I Perform DEB TACE on HCC, 17<sup>th</sup> Congresso da Sociedade Brasileira de Radiologia Intervencionista e Cirurgia Endovascular (SOBRICE), Campinas, Sao Paulo, Brazil, 5/2014

Cancer Ablation, Western Angiographic and Interventional Society, Kohala Coast, HI, 9/2014

Post Embolotherapy: Imaging Protocols/Follow-up/Clinical, Western Angiographic and Interventional Society, Kohala Coast, HI, 10/2014

Beyond Childs Pugh 7: Management Strategies in Advanced and Palliative Disease, Symposium on Hepatic Oncology at Whistler, Whistler, British Columbia, Canada, 1/2015

Panel: Multi-hit Therapy Advanced Disease: Y90/DEB/Sorafenib? Symposium on Hepatic Oncology at Whistler, Whistler, British Columbia, Canada, 1/2015

Post-embolotherapy: Imaging and Follow-up, Clinical and Contemporary IR 2015, Los Angeles, CA, 2/7/2015

Management of RCC Metastases, Society of Interventional Radiology Annual Scientific Meeting, Atlanta, GA, 3/1/2015

Biopsy in the Era of Personalized Cancer Medicine, Society of Interventional Radiology Annual Scientific Meeting, Atlanta, GA, 3/2/2015

Percutaneous Techniques for Managing Malignant Pleural Effusion, Ascites or Bowel Obstruction, World Conference on Interventional Oncology, New York, NY, 6/2015

Abscopal Effect: The Real Sasquatch, Western Angiographic and Interventional Society, Vancouver, British Columbia, Canada, 9/2015

Morbidity and Mortality Case, Western Angiographic and Interventional Society, Vancouver, British Columbia, Canada, 9/2015

Cervical Esophago Gastrostomies: Indications and Techniques, 23rd Advanced Interventional Management Symposium, New York, NY, 11/18/2015

Bone Ablation & Embolization, Society of Interventional Radiology Annual Scientific Meeting, Vancouver, Canada, 4/2016

Image-Guided Biopsy for Genetic Profiling, ECOG-ACRIN Spring 2016 Group Meeting, Boston, MA, 5/13/2016

Morbidity and Mortality Case, Western Angiographic and Interventional Society, Poipu Bay, HI, 9/11/2016

Morbidity and Mortality Case Panel, Tumor Ablation SA-CME Session, Western Angiographic and Interventional Society, Poipu Bay, HI, 9/13/2016

Image-guided biopsy for genetic profiling, Fall 2016 NCI CTEP Early Drug Development Meeting, Shady Grove, MD, 9/27/2016

Arterial Embolization in Bone and Soft Tissue Lesions, 9th Annual Symposium on Clinical Interventional Oncology, Hollywood, FL, 2/5/2017

Expert Demonstration: Embolization (Setup, Access, Mixing and Delivery), 9th Annual Symposium on Clinical Interventional Oncology, Hollywood, FL, 2/5/2017

Extreme IR: Case Presentation, Society of Interventional Radiology 2017 Annual Scientific Meeting, Washington, DC, 3/4/2017

Biopsy: When, Why, Where, How and How Often, Society of Interventional Radiology 2017 Annual Scientific Meeting, Washington, DC, 3/5/2017

HCC Genomics: Prospects for Enhancing HCC Management, Society of Interventional Radiology 2017 Annual Scientific Meeting, Washington, DC, 3/5/2017

Musculoskeletal Intervention: Basic Procedures the IR Should Know, Society of Interventional Radiology 2017 Annual Scientific Meeting, Washington, DC, 3/6/2017

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

MSK Interventions: Basic Procedures the IR Should Know, Association of Vascular and Interventional Radiographers Annual Meeting, Washington, DC, 3/7/2017

Nanotechnology and IRE in MSK: Shockingly Interesting Stuff, Society of Interventional Radiology 2017 Annual Scientific Meeting, Washington, DC, 3/7/2017

Panelist, Tumor Board Panel Discussion: Biopsy in the Era of Precision Medicine, Society of Interventional Radiology 2017 Annual Scientific Meeting, Washington, DC, 3/8/2017

Team Science: Critical Role of IR, Society of Interventional Radiology 2017 Annual Scientific Meeting, Washington, DC, 3/8/2017

Lung Tumor Biopsy: Pathology/Radiology Perspectives, NCI/DCTD Joint Pathology-Radiology Workshop: Best Practices for Lung and Liver Tumor Biopsies, Washington, DC, 5/2017

Different Flavors of IO Research, World Conference on Interventional Oncology, Boston, MA, 6/2017

Interventional Oncology Run Down, Western Angiographic and Interventional Society, Santa Barbara, CA, 9/12/2017

Interventional Oncology Series: Basic Science and Imaging. What's New in Non-Thermal Ablation (IRE), Radiological Society of North America 103rd Scientific Assembly and Annual Meeting, Chicago, IL, 11/2017

Buzzkill Corner: The Existential Threats to Interventional Oncology and the Possible Solutions, Symposium on Clinical Interventional Oncology, Hollywood, FL, 2/3/2018

Case Review: Bad Outcomes and Whether They Could Have Been Avoided, Symposium on Clinical Interventional Oncology, Hollywood, FL, 2/4/2018

Cases You Should Be Doing: Operator's Session on Lung Ablation, Symposium on Clinical Interventional Oncology, Hollywood, FL, 2/4/2018

Craftsman's Corner: Operator's Session in MSK Interventions, Symposium on Clinical Interventional Oncology, Hollywood, FL, 2/4/2018

Importance of Biopsy in the Era of Personalized Medicine, Symposium on Clinical Interventional Oncology, Hollywood, FL, 2/4/2018

Insanely Great Cases in IO, Symposium on Clinical Interventional Oncology, Hollywood, FL, 2/4/2018

Biopsy in the Era of Personalized Medicine, Society of Interventional Radiology 2018 Annual Scientific Meeting, Los Angeles, CA, 3/2018

MSK-Therapies That Should Be In Your Practice: Basic Bone Ablation, Society of Interventional Radiology 2018 Annual Scientific Meeting, Los Angeles, CA, 3/2018

Panelist, Best of WCIO, Society of Interventional Radiology 2018 Annual Scientific Meeting, Los Angeles, CA, 3/2018

The Hybrid Operating Room: Recent advances in the Utilization of the Hybrid OR at MD Anderson, 13th Annual Scientific Meeting of APSCVIR, Auckland, New Zealand, 3/8/2018

MSK Interventional Oncology: The Use of Ablation for Local Disease Control in MSK Metastases, 13th Annual Scientific Meeting of APSCVIR, Auckland, New Zealand, 3/9/2018

My Best and Worst Days in the Angio Suite: Lessons Learned in the Trenches, 17th Annual Scientific Meeting of CAIR, Calgary, Canada, 5/31/2018

Panelist, Interventional Oncology Workshop, 17th Annual Scientific Meeting of CAIR, Calgary, Canada, 5/31/2018

Ablation and Immune Therapy: Current State and Future Implications, 17th Annual Scientific Meeting of CAIR, Calgary, Canada, 6/1/2018

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

Evolving Role of IO in Metastatic Colorectal Carcinoma, 17th Annual Scientific Meeting of CAIR, Calgary, Canada, 6/1/2018

Panelist, Multidisciplinary Tumor Board: HCC, 17th Annual Scientific Meeting of CAIR, Calgary, Canada, 6/1/2018

How to Critically Review an Article, World Conference on Interventional Oncology, Boston, MA, 6/6/2018

Role of Image-Guided Biopsy in Oncology Clinical Trials, World Conference on Interventional Oncology, Boston, MA, 6/7/2018

Biopsy for Personalized Medicine, 4th Bangkok Conference in Interventional Oncology, Bangkok, Thailand, 9/6/2018

Bone IRE, 4th Bangkok Conference in Interventional Oncology, Bangkok, Thailand, 9/6/2018

Bone Metastases: Ablation for Pain Palliation and Local Tumor Control, 4th Bangkok Conference in Interventional Oncology, Bangkok, Thailand, 9/6/2018

Lung Ablation for Metastasis, 4th Bangkok Conference in Interventional Oncology, Bangkok, Thailand, 9/6/2018

Lung Biopsy - Basic, 4th Bangkok Conference in Interventional Oncology, Bangkok, Thailand, 9/6/2018

Cryoablation of RCC Metastasis, Spectrum 2018, Miami, FL, 11/2/2018

IRE in Bone Ablation: What Do We Know? Spectrum 2018, Miami, FL, 11/2/2018

IRE - New Opportunities, Musculoskeletal Interventional Oncology Interventions, SIR Foundation RCP Meeting, Fairfax, VA, 12/10/2018

Extreme IR, Society of Interventional Radiology Annual Scientific Meeting, Austin, TX, 3/23/2019

Compelling Conversations-Standards, Society of Interventional Radiology Annual Scientific Meeting, Austin, TX, 3/25/2019

Navigating Corporate Partnership: Connecting Women and Industry, Society of Interventional Radiology Annual Scientific Meeting, Austin, TX, 3/25/2019

SA-CME Tumor Ablation. Combinations of Embolization and Ablation: Are the Rewards Worth the Effort, Society of Interventional Radiology Annual Scientific Meeting, Austin, TX, 3/25/2019

Meet the Experts-Ablation, Society of Interventional Radiology Annual Scientific Meeting, Austin, TX, 3/26/2019

#### **Other, Including Scientific Exhibitions**

RSNA On-the-Air: The safety of traveling by air following lung biopsy, Radiological Society of North America 2008 Annual Meeting, Chicago, IL, 12/2008

**Tam AL.** Biocompatibles Speaker's Bureau: LC/DC bead-treating the liver for more than just liver cancer - Locoregional management of patient with metastatic melanoma & liver dominant disease, World Conference on Interventional Oncology, Philadelphia, PA, 6/2010

**Tam AL,** Ensor J, Ninan EP, Kaseb A, George M, Ready A, Narvaez A, Gupta S, Wallace MJ. Quality improvement initiative for patients undergoing transarterial chemoembolization (TACE), Radiological Society of North America, 96th Scientific Assembly and Annual Meeting, Chicago, IL, 12/2010

Shaw C, Bassett RL, Fox PS, Schmeler KM, Overman MJ, Wallace MJ, Gupta S, **Tam A.** Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites, MASCC/ISOO International Symposium on Supportive Care, New York, NY, 6/2012

Black BS, Jones AK, Bassett RL, Wallace MJ, **Tam AL,** Gupta S, Steele JR. Radiation dose during chemoembolization: A predictive model, American Association of Physicists in Medicine, Charlotte, NC, 7/2012



- Weksberg DC, Yang JN, **Tam AL**, McAleer MF, Li J, Ghia AJ, Wang XA, McRae SE, Settle SH, Rhines LD, Chang EL, Brown PD. Prospective assessment of treatment accuracy in spinal SBRT using implanted fiducial markers, American Radium Society 95<sup>th</sup> Annual Meeting, Scottsdale, AZ, 4/2013
- Overman MJ, Modak J, Kopetz S, Murthy R, Yao JC, Hicks ME, Abbruzzese JL, **Tam AL**. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? Global Academic Programs 2013 Conference, Houston, TX, 4/2013
- Gupta N, Patel AA, Ahrar K, Ahrar JU, **Tam AL**, Wallace MJ, Gupta S. Transarterial embolization of renal artery pseudoaneurysms following partial nephrectomy, Radiological Society of North America 99<sup>th</sup> Scientific Assembly and Annual Meeting, Chicago, IL, 12/2013
- Marsala A, **Tam A**, Galastri FL, Affonso BB, Nasser F, Wallace MJ, Odisio BC. Drug-eluting beads transarterial chemoembolization of the cystic artery: less scary than it sounds, Society of Interventional Radiology 39<sup>th</sup> Annual Scientific Meeting, San Diego, CA, 3/2014
- Sedrak L, **Tam A**, Odisio BC, Sabir S, Gupta S, Wallace MJ, Huang SY. Percutaneous transesophageal gastrostomy catheters: indication, technique, and outcome, Society of Interventional Radiology 39<sup>th</sup> Annual Scientific Meeting, San Diego, CA, 3/2014
- Appleton FT, Gu J, Gagea M, Ensor J, Muñoz N, Melancon T, Dixon K, McWatters A, **Tam A**. Characterization of nanopore formation after Irreversible Electroporation (IRE) in the porcine vertebral body, World Conference of Interventional Oncology, New York, NY, 5/8/2015
- Kim DW, Haymaker C, McQuail N, Sirmans E, Spencer C, Glitza I, Amaria R, Woodman S, Patel S, Davies MA, Yee C, Hwu WJ, Bernatchez C, Wargo J, Sharma P, Allison J, Hwu P, **Tam A**, Diab A. Pilot study of intratumoral cryoablation in combination with systemic checkpoint blockade in patients with metastatic melanoma, Society for Immunotherapy of Cancer 30<sup>th</sup> Anniversary Annual Meeting & Associated Programs, National Harbor, MD, 11/6/2015
- JVIR Podcast: Image-guided biopsy in the era of personalized cancer care-proceedings from the Society of Interventional Radiology Research Consensus panel, 1/2016
- Odisio BC, Cox, VL, Shai X, Ensor JE, Mahvash A, Jones AK, Gupta S, Faria SC, Wallace MJ, **Tam AL**, Murthy R. Incidental hepatic micronodules on cone beam CT angiography for high risk for local tumor progression, Boston, MA, 6/2016
- Gardner S, Ensor J, Huang SY, Ahrar K, Sabir SH, Gupta S, Lewis VO, **Tam AL**. Cryoablation for Local Disease Control of Renal Cell Carcinoma Bone Metastases, Western Conference on Interventional Oncology, Boston, MA, 6/10/2016
- Munoz NM, Minhaj AA, Golardi N, Jaso J, Ensor JE, Dixon K, Miller JJ, Feldman AR, Figueira TA, Galloway JR, Hill LR, Shelburne S, **Tam AL**. Irreversible electroporation combined with parenteral antibiotics enhances treatment of osteomyelitis caused by *S. aureus* in a rabbit model, Radiological Society of North America 103<sup>rd</sup> Scientific Assembly and Annual Meeting, Chicago, IL, 11/2017
- Transesophageal Gastrostomies & Other Heroic Palliative Care Procedures: Inications & Techniques, 25<sup>th</sup> Advanced Interventional Management Symposium, New York, NY, 11/8/2017
- Connors T, Sabir SH, **Tam A**, Ahrar K, Sheth R, Gupta S, Steele JR. Value of performing outpatient CT guided percutaneous lung biopsy at a large tertiary care center after unsuccessful outside hospital biopsy attempt, 43<sup>rd</sup> Annual Meeting of the Society of Interventional Radiology, Las Angeles, CA, 3/2018
- Khan M, Daileida TA, Kuban JD, Yevich SM, Huang SY, Sabir SH, Ahrar K, Tam AL, Gupta S, Sheth SA. Inferior vena cava filter placement practice patterns following the 2010 food and drug administration advisory, Cancer Imaging and Interventional Conference, Houston, TX, 4/2018

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

Cardenas N, Kuban J, Sheth S, McRae S, Ahrar J, **Tam AL**, Gupta S. Diagnostic accuracy of CT-guided transthoracic needle biopsy of pulmonary nodules measuring less than 7.5 mm, Cardiovascular and Interventional Radiological Society of Europe, Lisbon, Portugal, 9/2018

Sheth RA, Murthy R, Meric-Bernstam F, Hong D, Patel S, **Tam A**. Image-guided intra-tumoral delivery of immunotherapeutics: Interventional Radiology perspective, SITC 33rd Annual meeting, Washington, DC, 11/2018

#### **Seminar Invitations from Other Institutions**

Lecture, Engineering Research Center for Computer-Integrated, John Hopkins University, Baltimore, MD, 6/2015

Lecture, VISE Seminar Series, Biomedical Engineering, Vanderbilt University, Nashville, TN, 11/2015

#### **Lectureships and Visiting Professorships**

The Changing Face of Biopsy, Oncology Lecture Series, GlaxoSmithKline, Collegeville, PA, 11/3/2014

Abscopal Effect: The Real Sasquatch, Mayo Clinic, Visiting Professor, Radiology, Rochester, MN, 1/12/2016

The Changing Face of Image-guided Biopsy, Mayo Clinic, Visiting Professor, Radiology, Rochester, MN, 1/12/2016

Irreversible Electroporation: Applications for Bone, Mayo Clinic, Visiting Professor, Radiology, Rochester, MN, 1/13/2016

Nanoembolization + ablation; Lipiodol-irinotecan, Guerbet Lipiodol Research Summit, Lafayette Hill, PA, 10/15/2016

#### **Other Presentations at State and Local Conferences**

Surgical Decision Making in Necrotizing Enterocolitis and Focal Intestinal Perforation: Predictive Value of Radiologic Findings (Oral Presentation), 35<sup>th</sup> Annual Meeting of Pacific Association of Pediatric Surgeons, La Jolla, CA, 5/2002

Tam A, Ensor JE, Ninan E, Kaseb A, George M, Ready A, Hamlin A, Gupta S, Wallace MJ. Quality Improvement Initiative for Patients Undergoing Transarterial Chemoembolization (TACE), Innovation in Health Care Delivery Systems Symposium, The University of Texas at Austin McCombs School of Business, Austin, TX, 4/2012

Interventional Radiology: Helping Patients Pursue Personalized Cancer Therapy, Karolinska Institute and MD Anderson Cancer Center Global Academic Programs 2<sup>nd</sup> Collaborative Workshop, MD Anderson Cancer Center and Karolinska Institute, Houston, TX, 6/2012

Beyond Childs Pugh 7: Management Strategies in Advanced and Palliative Disease, MD Anderson Cancer Center Global Academic Programs, Houston, TX, 5/2015

The Role of Interventional Radiology Plays in Lung Cancer Management -- MDACC Experience, Lung Cancer Workshop for Chinese Physicians, The University of Texas MD Anderson Cancer Center, Global Academic Programs, Houston, TX, 8/13/2015

Ablation for MSK metastases-Palliation and Beyond, Medtronic Advanced Ablation Solutions, Covidien, Dallas, TX, 11/5/2015

Bone Metastases: RFA, Cryoablation, Laser or Microwave: Why, When and How, Cancer Imaging and Interventions Conference, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2018

Lung Ablation: Case Presentations, Cancer Imaging and Interventions Conference, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2018

Lung Metastases: Outcomes of Ablative Therapy, Cancer Imaging and Interventions Conference, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2018

Tissue Biopsy, September Master Class, MD Anderson Cancer Center, Houston, TX, 9/26/2018

**PROFESSIONAL MEMBERSHIPS/ACTIVITIES**

**Professional Society Activities, with Offices Held**

**National and International**

- Radiological Society of North America (RSNA), Oak Brook, IL
  - Member, 2002-present
  - Member, Vascular/Interventional Subcommittee of the Scientific Program Committee, 12/2016-12/2019
- American College of Radiology
  - Member, 2005-present
  - Member, ACR-RSNA Public Information Website Committee, 6/2017-present
  - Member, IR Commission Committee, 6/2017-present
- Royal College of Physicians and Surgeons of Canada, Ottawa, Canada
  - Member, 2005-present
- Society of Interventional Radiology (SIR), Fairfax, VA
  - Member, 2005-present
  - Member, Health Systems Outreach Committee, 2009-2012
  - Member, Joint Commission's Hospital Care Professional and Technical Advisory Committee (PTAC), 2011-2016
  - Chair, Health Systems Outreach Committee, 2012-2015
  - Abstract Reviewer for Annual Meeting, 2013-2016
  - Hands-on Workshop Liaison for the Annual Meeting Committee, 2013-2016
  - Member, Grants Research & Education Division, 4/2015-present
  - Executive Council, 3/2017-3/2020
  - Standards Division Councilor, 3/2017-3/2020
- Western Angiographic & Interventional Society, Oakland, CA
  - Member, 2006-present
  - Western Angiographic and Interventional Society Officer, 2014-2018
  - Vice President, 2015-2016
  - President, 2016-2017
  - Past President, 2017-2018
- ASCO Working Group on Developing the Evidence for the Comparative Effectiveness of Cancer Treatment Modalities
  - Member, 2015-present
- ECOG-ACRIN, NCI-MATCH Imaging Working Group
  - Member, 2015-present
- Society of Interventional Oncology
  - Member, 2017-present
  - Member, Scientific Program Committee for WCIO Meeting, 2018-present
- American Society of the Digestive Disease Interventions
  - Member, Foundations Committee, 9/2017-present
- American Board of Radiology
  - Interventional Radiology Board Examiner, 2018-present
- ASCO Working Group on Exploratory Research Biopsies
  - Member, 2018-present

**Local/State**

- Harris County Medical Society, Houston, TX
  - Member, 7/2006
- Texas Medical Association, TX
  - Member, 7/2006

Alda L. Tam, M.D., M.B.A., F.R.C.P.C., F.S.I.R.

**UNIQUE ACTIVITIES**  
N/A

**DATE OF LAST CV UPDATE**  
4/11/2019